PT J
AU McCarty, MF
AF McCarty, MF
TI A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk
SO MEDICAL HYPOTHESES
LA English
DT Article
ID alpha-glucosidase inhibitors; caffeine-induced impairment; moderate alcohol intake; insulin-producing cells; dietary glycemic index; pancreatic beta-cells; cancer risk; transcription factor; tolerance; humans
AB Recent prospective epidemiology links heavy coffee consumption to a substantial reduction in risk for type 2 diabetes. Yet there is no evidence that coffee improves insulin sensitivity and, at least in acute studies, caffeine has a negative impact in this regard. Thus, it is reasonable to suspect that coffee influences the risk for beta cell "failure" that precipitates diabetes in subjects who are already insulin resistant. Indeed, there is recent evidence that coffee increases production of the incretin hormone glucagon-like peptide-1 (GLP-1), possibly owing to an inhibitory effect of chlorogenic acid (CGA - the chief polyphenol in coffee) on glucose absorption. GLP-1 acts on beta cells, via cAMP-dependent mechanisms, to promote the synthesis and activity of the transcription factor IDX-1, crucial for maintaining the responsiveness of beta cells to an increase in plasma glucose. Conversely, the "glucolipotoxicity" thought to initiate and sustain beta cell dysfunction in diabetics can suppress expression of this transcription factor. The increased production of GLP-1 associated with frequent coffee consumption could thus be expected to counteract the adverse impact of chronic free fatty acid overexposure on beta cell function in overweight insulin resistant subjects. CGA's putative impact on glucose absorption may reflect the ability of this compound to inhibit glucose-6-phosphate translocase 1, now known to play a role in intestinal glucose transport. Delayed glucose absorption may itself protect beta cells by limiting postprandial hyperglycemia - though, owing to countervailing effects of caffeine on plasma glucose, and a paucity of relevant research studies, it is still unclear whether coffee ingestion blunts the postprandial rise in plasma glucose. More generally, diets high in "lente carbohydrate", or administration of nutraceuticals/ pharmaceuticals which stow the absorption of dietary carbohydrate, should help preserve efficient beta cell function by boosting GLP-1 production, as well as by blunting the glucotoxic impact of postprandial. hyperglycemia on beta cell function. (c) 2004 Elsevier Ltd. All rights reserved.
C1 NutriGuard Res, Encinitas, CA 92024 USA.
RP McCarty, MF (corresponding author), 4622 Santa Fe St, San Diego, CA 92109 USA.
EM mccarty@pantox.com
CR Abraham EJ, 2002, ENDOCRINOLOGY, V143, P3152, DOI 10.1210/en.143.8.3152
   Ahren Bo, 2003, CURR DIAB REP, V3, P365, DOI 10.1007/s11892-003-0079-9
   AMMON HPT, 1991, ARCH PHARM, V324, P261, DOI 10.1002/ardp.19913240502
   Augustin LSA, 2003, CANCER CAUSE CONTROL, V14, P657, DOI 10.1023/A:1025676907942
   Augustin LSA, 2003, ANN ONCOL, V14, P78, DOI 10.1093/annonc/dkg022
   Augustin LSA, 2001, ANN ONCOL, V12, P1533, DOI 10.1023/A:1013176129380
   Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
   Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486
   Chu NV, 2002, DIABETES CARE, V25, P542, DOI 10.2337/diacare.25.3.542
   Cleophas TJ, 1999, BIOMED PHARMACOTHER, V53, P417, DOI 10.1016/S0753-3322(99)80121-8
   Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559
   Drucker DJ, 2003, DIABETES CARE, V26, P2929, DOI 10.2337/diacare.26.10.2929
   El-Assaad W, 2003, ENDOCRINOLOGY, V144, P4154, DOI 10.1210/en.2003-0410
   Enç FY, 2001, AM J PHYSIOL-GASTR L, V281, PG752, DOI 10.1152/ajpgi.2001.281.3.G752
   FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115
   FEINBERG LJ, 1968, METABOLISM, V17, P916, DOI 10.1016/0026-0495(68)90158-3
   Folsom AR, 2003, NUTR CANCER, V46, P119, DOI 10.1207/S15327914NC4602_03
   Franceschi S, 2001, ANN ONCOL, V12, P173, DOI 10.1023/A:1008304128577
   Gault VA, 2003, BIOCHEM BIOPH RES CO, V308, P207, DOI 10.1016/S0006-291X(03)01361-5
   GOKE B, 1994, EUR J CLIN INVEST, V24, P25
   GOLDMAN JA, 1969, OBSTET GYNECOL, V33, P214
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261
   Habener JF, 2002, DRUG NEWS PERSPECT, V15, P491, DOI 10.1358/dnp.2002.15.8.740224
   Hemmerle H, 1997, J MED CHEM, V40, P137, DOI 10.1021/jm9607360
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   JANKELSON OM, 1967, LANCET, V1, P527
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   KAWACHI I, 1994, BRIT HEART J, V72, P269
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Lapidot TM, 2002, J AGR FOOD CHEM, V50, P7220, DOI 10.1021/jf020615a
   Lebovitz HE, 1997, ENDOCRIN METAB CLIN, V26, P539, DOI 10.1016/S0889-8529(05)70266-8
   Lee SC, 2002, J AGR FOOD CHEM, V50, P6618, DOI 10.1021/jf020189t
   LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878
   MacDonald PE, 2002, DIABETES, V51, PS434, DOI 10.2337/diabetes.51.2007.S434
   Michaud DS, 2002, J NATL CANCER I, V94, P1293, DOI 10.1093/jnci/94.17.1293
   Nardini M, 2002, J AGR FOOD CHEM, V50, P5735, DOI 10.1021/jf0257547
   OLSON LK, 1995, P NATL ACAD SCI USA, V92, P9127, DOI 10.1073/pnas.92.20.9127
   Olthof MR, 2003, J NUTR, V133, P1806, DOI 10.1093/jn/133.6.1806
   Olthof MR, 2001, J NUTR, V131, P66, DOI 10.1093/jn/131.1.66
   Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657
   Ranganath L, 1998, DIABETIC MED, V15, P120, DOI 10.1002/(SICI)1096-9136(199802)15:2<120::AID-DIA529>3.0.CO;2-I
   Roduit R, 2000, J BIOL CHEM, V275, P35799, DOI 10.1074/jbc.M006001200
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545
   Santer R, 2003, GASTROENTEROLOGY, V124, P34, DOI 10.1053/gast.2003.50009
   Scheen AJ, 2003, DRUGS, V63, P933, DOI 10.2165/00003495-200363100-00002
   Seifarth C, 1998, DIABETIC MED, V15, P485, DOI 10.1002/(SICI)1096-9136(199806)15:6<485::AID-DIA610>3.0.CO;2-Y
   Seufert J, 1998, J CLIN INVEST, V101, P2528, DOI 10.1172/JCI2401
   Sierksma A, 2004, DIABETES CARE, V27, P184, DOI 10.2337/diacare.27.1.184
   Stoffers DA, 2000, DIABETES, V49, P741, DOI 10.2337/diabetes.49.5.741
   Stümpel F, 2001, P NATL ACAD SCI USA, V98, P11330, DOI 10.1073/pnas.211357698
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219
   TRUSWELL AS, 1992, EUR J CLIN NUTR S2, V46, P91
   UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van de Wiel A, 1998, NETH J MED, V52, P91, DOI 10.1016/S0300-2977(97)00087-9
   Vuksan V, 2000, DIABETES CARE, V23, P9, DOI 10.2337/diacare.23.1.9
   Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327
   Wang XL, 1999, ENDOCRINOLOGY, V140, P4904, DOI 10.1210/en.140.10.4904
   Wang XL, 2001, ENDOCRINOLOGY, V142, P1820, DOI 10.1210/en.142.5.1820
   WELSCH CA, 1989, J NUTR, V119, P1698, DOI 10.1093/jn/119.11.1698
   Yoshida S, 2002, DIABETES, V51, P2505, DOI 10.2337/diabetes.51.8.2505
   Zangen DH, 1997, DIABETES, V46, P258, DOI 10.2337/diabetes.46.2.258
   Zhou J, 2002, J CELL PHYSIOL, V192, P304, DOI 10.1002/jcp.10143
NR 68
TC 136
Z9 151
U1 1
U2 35
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUN 15
PY 2005
VL 64
IS 4
BP 848
EP 853
DI 10.1016/j.mehy.2004.03.037
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 906SP
UT WOS:000227663500027
PM 15694706
DA 2025-04-28
ER

PT J
AU Kobayashi-Hattori, K
   Mogi, A
   Matsumoto, Y
   Takita, T
AF Kobayashi-Hattori, K
   Mogi, A
   Matsumoto, Y
   Takita, T
TI Effect of caffeine on the body fat and lipid metabolism of rats fed on a high-fat diet
SO BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE caffeine; body fat; lipid metabolism; catecholamine; obesity
ID serum-cholesterol; green tea; plasma-lipids; mice; beverages; excretion; obesity; coffee
AB The intake of caffeine (CF) at 0.025, 0.05 or 0.1 % for 21 days progressively reduced the body fat mass and body fat percentage in Sprague-Dawley (SD) rats fed on a high-fat diet with increasing administration level. Moreover, CF increased the serum concentrations of catecholamines and free fatty acids in SD rats orally administered with CF (5 mg/kg). These results suggest that the intake of CF reduced body fat by lipolysis via catecholamines. CF has potential as a functional food ingredient with an anti-obesity action.
C1 Tokyo Univ Agr, Fac Appl Biosci, Dept Nurtrit Sci, Setagaya Ku, Tokyo 1568502, Japan.
   Kawasaki Univ Med Welf, Fac Med Profess, Dept Clin Nutr, Kurashiki, Okayama 7010193, Japan.
C3 Tokyo University of Agriculture
RP Tokyo Univ Agr, Fac Appl Biosci, Dept Nurtrit Sci, Setagaya Ku, Tokyo 1568502, Japan.
EM k2kobaya@nodai.ac.jp
CR Adachi H, 2005, J EPIDEMIOL, V15, P85, DOI 10.2188/jea.15.85
   ARCIERO PJ, 1995, ENDOCRINOL METAB, V31, P0
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Benowitz NL, 1995, CLIN PHARMACOL THER, V58, P684, DOI 10.1016/0009-9236(95)90025-X
   BUKOWIECKI LJ, 1983, AM J PHYSIOL, V244, PR500, DOI 10.1152/ajpregu.1983.244.4.R500
   CHEN MD, 1994, CHIN MED J, V53, P257
   DENARO CP, 1991, EUR J CLIN PHARMACOL, V40, P273, DOI 10.1007/BF00315208
   FEARS R, 1978, BRIT J NUTR, V39, P363, DOI 10.1079/BJN19780046
   Hasegawa N, 2000, J HEALTH SCI, V46, P153
   He Y, 2004, ANN EPIDEMIOL, V14, P1, DOI 10.1016/S1047-2797(03)00069-3
   HENLY AA, 1957, ANALYST, V82, P286
   HOSTMARK AT, 1988, NUTR REP INT, V38, P859
   HOSTMARK AT, 1986, NUTR REP INT, V34, P119
   INOUE H, 2005, ITE LETT BATT NEW TE, V6, P61
   Kogure A, 2002, CLIN EXP PHARMACOL P, V29, P391, DOI 10.1046/j.1440-1681.2002.03675.x
   LeBlanc J, 1995, PHARMACOL RES, V32, P129, DOI 10.1016/S1043-6618(05)80005-2
   LIN BB, 1986, NUTR REP INT, V34, P821
   Michna L, 2003, LIFE SCI, V73, P1383, DOI 10.1016/S0024-3205(03)00468-5
   NAISMITH DJ, 1969, J NUTR, V97, P375, DOI 10.1093/jn/97.3.375
   ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403
   SUGIYAMA K, 1989, AGR BIOL CHEM TOKYO, V53, P3101, DOI 10.1080/00021369.1989.10869788
   Welborn TA, 2003, MED J AUSTRALIA, V179, P580, DOI 10.5694/j.1326-5377.2003.tb05704.x
   Yoshiike N, 2002, ASIA PAC J CLIN NUTR, V11, PS727, DOI 10.1046/j.1440-6047.11.s8.18.x
   ZAK B, 1957, AM J CLIN PATHOL, V27, P583, DOI 10.1093/ajcp/27.5_ts.583
   Zheng GD, 2004, IN VIVO, V18, P55
NR 25
TC 71
Z9 83
U1 1
U2 24
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0916-8451
EI 1347-6947
J9 BIOSCI BIOTECH BIOCH
JI Biosci. Biotechnol. Biochem.
PD NOV 15
PY 2005
VL 69
IS 11
BP 2219
EP 2223
DI 10.1271/bbb.69.2219
PG 5
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry, Applied; Food Science & Technology
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Chemistry; Food Science & Technology
GA 989YU
UT WOS:000233710900026
PM 16306706
DA 2025-04-28
ER

PT J
AU van Dam, RM
   Hu, FB
AF van Dam, RM
   Hu, FB
TI Coffee consumption and risk of type 2 diabetes - A systematic review
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID caffeine-induced impairment; glucose-tolerance; chlorogenic acid; blood-glucose; insulin action; life-style; metaanalysis; ingestion; plasma; men
AB Context Emerging epidemiological evidence suggests that higher coffee consumption may reduce the risk of type 2 diabetes. Objective To examine the association between habitual coffee consumption and risk of type 2 diabetes and related outcomes. Data Sources and Study Selection We searched MEDLINE through January 2005 and examined the reference lists of the retrieved articles. Because this review focuses on studies of habitual coffee consumption and risk of type 2 diabetes, we excluded studies of type 1 diabetes, animal studies, and studies of short-term exposure to coffee or caffeine, leaving 15 epidemiological studies (cohort or cross-sectional). Data Extraction Information on study design, participant characteristics, measurement of coffee consumption and outcomes, adjustment for potential confounders, and estimates of associations was abstracted independently by 2 investigators. Data Synthesis We identified 9 cohort studies of coffee consumption and risk of type 2 diabetes, including 193 473 participants and 8394 incident cases of type 2 diabetes, and calculated summary relative risks (RRs) using a random-effects model. The RR of type 2 diabetes was 0.65 (95% confidence interval [CI], 0. 54-0.78) for the highest (>= 6 or >= 7 cups per day) and 0.72 (95% Cl, 0.62-0.83) for the second highest (4-6 cups per day) category of coffee-consumption compared with the lowest consumption category (0 or <= 2 cups per day). These associations did not differ substantially by sex, obesity, or region (United States and Europe). In the cross-sectional studies conducted in northern Europe, southern Europe, and Japan, higher coffee consumption was consistently associated with a lower prevalence of newly detected hyperglycemia, particularly postprandial hyperglycemia. Conclusions This systematic review supports the hypothesis that habitual coffee consumption is associated with a substantially lower risk of type 2 diabetes. Longer-term intervention studies of coffee consumption and glucose metabolism are warranted to examine the mechanisms underlying the relationship between coffee consumption and type 2 diabetes.
C1 Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Nutr & Hlth, Amsterdam, Netherlands.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Vrije Universiteit Amsterdam
RP Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave,Bldg 2, Boston, MA 02115 USA.
EM rvan-dam@hsph.harvard.edu
FU NIDDK NIH HHS [DK58845] Funding Source: Medline
CR Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x
   Andrade-Cetto A, 2001, J ETHNOPHARMACOL, V78, P145, DOI 10.1016/S0378-8741(01)00335-X
   Unknown -, 1900, DOI 10.1002/(SICI)1097-0258(20000215)19:3335::AID-SIM3363.0.CO;2-Z, V0, P0
   Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   Bracken MB, 2002, EPIDEMIOLOGY, V13, P165, DOI 10.1097/00001648-200203000-00011
   BROWN CR, 1989, PHARMACOL BIOCHEM BE, V34, P565, DOI 10.1016/0091-3057(89)90559-5
   Carlsson S, 2004, INT J EPIDEMIOL, V33, P616, DOI 10.1093/ije/dyh185
   Ceriello A, 2004, ARTERIOSCL THROM VAS, V24, P816, DOI 10.1161/01.ATV.0000122852.22604.78
   Clifford MN, 2000, J SCI FOOD AGR, V80, P1118, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1118::AID-JSFA570>3.0.CO;2-9
   de Paulis T, 2002, EUR J PHARMACOL, V442, P215, DOI 10.1016/S0014-2999(02)01540-6
   de Sotillo DVR, 2002, J NUTR BIOCHEM, V13, P717, DOI 10.1016/S0955-2863(02)00231-0
   de Valk HW, 1999, NETH J MED, V54, P139, DOI 10.1016/S0300-2977(99)00005-4
   deGroot JGAJ, 1996, EUR J CLIN NUTR, V50, P0
   DENARO CP, 1991, EUR J CLIN PHARMACOL, V40, P273, DOI 10.1007/BF00315208
   Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   Graham TE, 1998, J APPL PHYSIOL, V85, P883, DOI 10.1152/jappl.1998.85.3.883
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   KAWACHI I, 1994, BRIT HEART J, V72, P269
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Koppes LLJ, 2005, DIABETES CARE, V28, P719, DOI 10.2337/diacare.28.3.719
   Lane JD, 2004, DIABETES CARE, V27, P2047, DOI 10.2337/diacare.27.8.2047
   *NAT COFF ASS, 2002, NAT COFF DRINK TREND, V0, P0
   NATHAN DM, 1993, NEW ENGL J MED, V328, P1676, DOI 10.1056/NEJM199306103282306
   PIETINEN P, 1988, PREV MED, V17, P183, DOI 10.1016/0091-7435(88)90062-X
   Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657
   Pulido R, 2003, EUR J CLIN NUTR, V57, P1275, DOI 10.1038/sj.ejcn.1601685
   Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Robinson LE, 2004, J NUTR, V134, P2528, DOI 10.1093/jn/134.10.2528
   Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1111/j.0014-3820.2005.tb01004.x
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Schaafsma G, 1989, VOEDING, V50, P223
   Schaefer B, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00016
   Shearer J, 2003, J NUTR, V133, P3529, DOI 10.1093/jn/133.11.3529
   Soriguer F, 2004, ANN INTERN MED, V141, P321, DOI 10.7326/0003-4819-141-4-200408170-00017
   Sutton AJ, 2000, STAT METHODS MED RES, V9, P421, DOI 10.1191/096228000701555244
   Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562
   Tavani A, 2000, EUR J CANCER PREV, V9, P241, DOI 10.1097/00008469-200008000-00004
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   Urgert R, 1996, BRIT MED J, V313, P1362, DOI 10.1136/bmj.313.7069.1362
   van Dam RM, 2004, DIABETOLOGIA, V47, P2152, DOI 10.1007/s00125-004-1573-6
   Van Dam RM, 2004, DIABETES CARE, V27, P2990, DOI 10.2337/diacare.27.12.2990
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van Dam RM, 2003, ANN NUTR METAB, V47, P627
   van Houwelingen HC, 2002, STAT MED, V21, P589, DOI 10.1002/sim.1040
   WACHMAN A, 1970, METABOLIS, V19, P539, DOI 10.1016/0026-0495(70)90009-0
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Yamaji T, 2004, DIABETOLOGIA, V47, P2145, DOI 10.1007/s00125-004-1590-5
   Yoshioka K, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12585-8
NR 62
TC 497
Z9 534
U1 1
U2 92
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 6
PY 2005
VL 294
IS 1
BP 97
EP 104
DI 10.1001/jama.294.1.97
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 941JD
UT WOS:000230210200030
PM 15998896
DA 2025-04-28
ER

PT J
AU Vukovich, MD
   Schoorman, R
   Heilman, C
   Jacob, P
   Benowitz, NL
AF Vukovich, MD
   Schoorman, R
   Heilman, C
   Jacob, P
   Benowitz, NL
TI Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE caffeine; dietary supplement; ephedrine; herbal medicine; Ma Huang
ID central-nervous-system; double-blind; weight-loss; dietary-supplements; ma huang; safety; efficacy; placebo; obese; thermogenesis
AB 1. The purpose of the present study was to determine whether the consumption of an acute dose of caffeine and Ma Huang increases resting energy expenditure (REE), heart rate (HR) and blood pressure (BP) over a 3 h period. 2. A randomized, double-blind cross-over study was performed evaluating the acute effects of caffeine (150 mg)/herbal ephedra (Ma Huang; 20 mg ephedra alkaloids) versus a placebo. A total of eight healthy subjects (four males and four females) with a mean (+/-SD) age of 23.4 +/- 0.8 years (mean ages for males and females: 25.3 +/- 0.7 and 22.0 +/- 0.7 years, respectively) and 22.5 +/- 3.1% body fat (15.7 +/- 1.2 and 27.6 +/- 3.5% body fat for males and females, respectively) were recruited to the study. Participants were moderate caffeine users (approximately 150-300 mg/day). 3. Subjects reported to the laboratory following a 12 h fast and 48 h of a caffeine-free diet. Resting energy expenditure was measured prior to supplementation and for 15 min every 30 min for 3 h following supplementation. Heart rate and BP were obtained every 15 min. Blood samples were obtained every 30 min following the measurement of REE and analysed for caffeine, ephedrine, free fatty acids and glucose. 4. By 3 h, HR was 22.7 +/- 5.5% higher (P < 0.05) than baseline for the caffeine/ephedra trial compared with 8.9 +/- 2.2% higher for the placebo grou. At 3 h, systolic BP was 9.1 +/- 2.2% higher (P < 0.05) than baseline for the caffeine/ephedra trial compared with only 1.9 +/- 2.9% different from baseline for the placebo trial. There was no effect of the caffeine/ephedra combination on diastolic BP. Resting energy expenditure during the last 30 min was 4.5 +/- 2.5% higher in the placebo trial and 10.7 +/- 2.5% higher (P < 0.05) in the caffeine/ephedra trial; REE was 8.5 +/- 2.0% higher (P < 0.05) in the caffeine/ephedra trial compared with the placebo trial. Free fatty acids increased over time in the placebo and caffeine/ephedra trials (from 0.5 +/- 0.05 to 0.63 +/- 0.05 mEq/L and from 0.48 +/- 0.06L to 0.8 +/- 0.05 mEq/L, respectively). 5. Caffeine and herbal ephedra, at doses of 150 mg and 20 mg (ephedrine), respectively, result in a significant elevation in REE, HR and BP. Although significant, the increase in energy expenditure is negligible in terms of weight loss.
C1 S Dakota State Univ, Dept Hlth Phys Educ & Recreat, Appl Physiol Lab, Brookings, SD 57007 USA.
   Univ Calif San Francisco, San Francisco Gen Hosp, Div Clin Pharmacol, San Francisco, CA USA.
C3 South Dakota State University; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center
RP S Dakota State Univ, Dept Hlth Phys Educ & Recreat, Appl Physiol Lab, Box 2820, Brookings, SD 57007 USA.
EM matt.vukovich@sdstate.edu
FU National Institute on Drug Abuse [P30DA012393] Funding Source: NIH RePORTER; NIDA NIH HHS [DA02277, DA012393] Funding Source: Medline
CR Armstrong WJ, 2001, JOURNAL OF EXERCISE PHYSIOLOGY ONLINE, V4, P28
   ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1992, METABOLISM, V41, P686, DOI 10.1016/0026-0495(92)90304-S
   ASTRUP A, 1990, CURR THER RES CLIN E, V48, P1087
   Boozer CN, 2001, INT J OBESITY, V25, P316, DOI 10.1038/sj.ijo.0801539
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   BYE C, 1974, BRIT J CLIN PHARMACO, V1, P71, DOI 10.1111/j.1365-2125.1974.tb00209.x
   DALY PA, 1993, INT J OBESITY, V17, P0
   DULLOO AG, 1986, INT J OBESITY, V10, P467
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523
   Horton TJ, 1996, INT J OBESITY, V20, P91
   Jacob P, 2004, J ANAL TOXICOL, V28, P152, DOI 10.1093/jat/28.3.152
   Kalman D, 2002, INT J OBESITY, V26, P1363, DOI 10.1038/sj.ijo.0802061
   KRIEGER DR, 1990, T ASSOC AM PHYSICIAN, V53, P307
   LIU YL, 1995, INT J OBESITY, V19, P678
   MARTIN WR, 1971, CLIN PHARMACOL THER, V12, P245
   PASQUALI R, 1985, INT J OBESITY, V9, P93
   Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12
   Shannon JR, 1999, CLIN SCI, V96, P483, DOI 10.1042/CS19980206
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
NR 23
TC 38
Z9 43
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
EI 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD JAN-FEB 15
PY 2005
VL 32
IS 1-2
BP 47
EP 53
DI 10.1111/j.1440-1681.2005.04152.x
PG 7
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA 900XX
UT WOS:000227248700009
PM 15730434
DA 2025-04-28
ER

PT J
AU Rajeshwari, R
   Yang, SJ
   Nicklas, TA
   Berenson, GS
AF Rajeshwari, R
   Yang, SJ
   Nicklas, TA
   Berenson, GS
TI Secular trends in children's sweetened-beverage consumption (1973 to 1994): The Bogalusa heart study
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID body-mass index; nutrition examination surveys; energy-intake; national-health; food-intake; young adulthood; united-states; risk-factors; obesity; adolescents
AB Objective To determine whether children's sweetened-beverage consumption has changed over a 21-year period (1973 to 1994) in Bogalusa, LA, and whether trends in energy intake, milk consumption, and body mass index (BMI) varied among the sweetened-beverage consumption groups. Design Information on food and nutrient intake was derived from a single 24-hour dietary recall collected from children who participated in one of seven cross-sectional surveys. Subjects/Setting A total of 1,548 10-year-old children (65% white, 35% African American; 51% female, 49% male) were randomly selected to participate in the study. Statistical Analyses The Cochran-Armitage Trend test was applied to examine the trends in sweetened-beverage consumption by 10-year-old children over a 21-year period. A general linear model was used to examine the trend in milk consumption, energy intake, and BMI among the sweetened-beverage consumption groups. Results The percentage of children consuming sweetened beverages significantly decreased from 83% (1973) to 81% (1994) (P<.05), particularly consumption of soft drinks (P<.01) and coffee with sugar (P<.0001). However, the mean gram amount of tea with sugar consumed significantly increased (P<.0001), with no changes in the mean gram amount of fruit drinks, soft drinks, and coffee with sugar consumed. When comparing tertiles of sweetened-beverage consumption over time, the mean gram consumption significantly increased from 1973 to 1994 for those children who were in the medium (P<.001) to high (P<.0001) tertiles. The mean BMI significantly increased (P<.001) from 1973 to 1994 in children within all of the sweetened-beverage consumption groups; however, there were no significant differences in total BMI across the sweetened-beverage consumption groups. The total gram amount of milk consumption was significantly lower in the medium to high sweetened-beverage consumption groups compared with the lower to no sweetened-beverage consumption groups. Total energy intake remained unchanged from 1973 to 1994 within all four sweetened-beverage consumption groups. Total energy intake was significantly higher in the high sweetened-beverage consumption group compared with the other three sweetened-beverage consumption groups. Conclusions Children's sweetened-beverage consumption has changed over a 21-year period. The percentage of children consuming sweetened beverages decreased from 1973 to 1994, particularly consumption of soft drinks and coffee with sugar. Data suggest that there was no linear relationship between sweetened-beverage consumption and BMI and total energy intake. However, total milk consumption was lower in the medium to high sweetened-beverage consumption groups compared with the low to no consumption groups. More studies are needed to confirm these regional findings, which may not be reflective of national trends.
C1 Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, Houston, TX 77030 USA.
   Tulane Ctr Cardiovasc Hlth, Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA.
C3 Baylor College of Medicine; Tulane University; Tulane University Hospital
RP Baylor Coll Med, Dept Pediat, Childrens Nutr Res Ctr, 1100 Bates Ave, Houston, TX 77030 USA.
EM tnicklas@bcm.tmc.edu
FU NHLBI NIH HHS [R01 HL38844] Funding Source: Medline; NIA NIH HHS [AG16592] Funding Source: Medline
CR Ariza AJ, 2004, J URBAN HEALTH, V81, P150, DOI 10.1093/jurban/jth091
   Ballew C, 2000, ARCH PEDIAT ADOL MED, V154, P1148, DOI 10.1001/archpedi.154.11.1148
   Berenson GS, 1986, CAUSATION CARDIOVASC, V0, P0
   Berenson GS, 1980, CARDIOVASCULAR RISK FACTORS IN CHILDREN: THE EARLY NATURAL HISTORY OF ATHEROSCLEROSIS AND ESSENTIAL HYPERTENSION, V0, P0
   Bowman SA, 1999, FAMILY EC NUTR REV, V12, P31
   Bowman SA, 2002, J AM DIET ASSOC, V102, P1234, DOI 10.1016/S0002-8223(02)90273-7
   Braam LAJLM, 1998, AM J EPIDEMIOL, V147, P1081, DOI 10.1093/oxfordjournals.aje.a009402
   Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157
   Briefel RR, 1997, AM J CLIN NUTR, V65, P1203
   Cavadini C, 2000, ARCH DIS CHILD, V83, P18, DOI 10.1136/adc.83.1.18
   Demory-Luce D, 2004, J AM DIET ASSOC, V104, P1684, DOI 10.1016/j.jada.2004.07.026
   Farris R, 1993, TXB PEDIAT NUTR, V2nd, P505
   Ferraro KF, 2003, J GERONTOL B-PSYCHOL, V58, PS110, DOI 10.1093/geronb/58.2.S110
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   FLEMING KH, 1994, J NUTR, V124, PS1426, DOI 10.1093/jn/124.suppl_8.1426S
   Forshee RA, 2003, INT J FOOD SCI NUTR, V54, P297, DOI 10.1080/09637480120092143
   FRANK GC, 1977, J AM DIET ASSOC, V71, P26
   Freedman DS, 1997, PEDIATRICS, V99, P420, DOI 10.1542/peds.99.3.420
   FREEDMAN DS, 1987, AM J PUBLIC HEALTH, V77, P588, DOI 10.2105/AJPH.77.5.588
   GERRIOR S, 1998, FOOD REV, V21, P29
   Gibson SA, 1996, INT J FOOD SCI NUTR, V47, P405, DOI 10.3109/09637489609006954
   GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X
   GUO SS, 1994, AM J CLIN NUTR, V59, P810, DOI 10.1093/ajcn/59.4.810
   Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6
   Heerstrass DW, 1998, INT J EPIDEMIOL, V27, P186, DOI 10.1093/ije/27.2.186
   Johansson G, 2001, PUBLIC HEALTH NUTR, V4, P919, DOI 10.1079/PHN2001124
   Johnson RK, 1998, J AM DIET ASSOC, V98, P1136, DOI 10.1016/S0002-8223(98)00263-6
   Johnson RK, 2002, J AM DIET ASSOC, V102, P853, DOI 10.1016/S0002-8223(02)90192-6
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   Macdiarmid JI, 1998, INT J OBESITY, V22, P1053, DOI 10.1038/sj.ijo.0800724
   Moore MC, 1982, EXTENDED TABLE NUTR, V0, P0
   Nicklas TA, 2003, AM J PREV MED, V25, P9, DOI 10.1016/S0749-3797(03)00098-9
   Overby NC, 2004, PUBLIC HEALTH NUTR, V7, P285, DOI 10.1079/PHN2003515
   Rampersaud GC, 2003, J AM DIET ASSOC, V103, P97, DOI 10.1053/jada.2003.50006
   Roberts SB, 2002, J AM COLL NUTR, V21, P140S, DOI 10.1080/07315724.2002.10719211
   SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014
   Storey ML, 2003, INT J FOOD SCI NUTR, V54, P491, DOI 10.1080/09637480310001622350
   Thompson B, 1999, J AM DIET ASSOC, V99, P1241, DOI 10.1016/S0002-8223(99)00306-5
   THOMPSON FE, 1994, J NUTR, V124, PS2245, DOI 10.1093/jn/124.suppl_11.2245s
   TORDOFF MG, 1990, AM J CLIN NUTR, V51, P963, DOI 10.1093/ajcn/51.6.963
   TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005
   Troiano RP, 2000, AM J CLIN NUTR, V72, P1343S, DOI 10.1093/ajcn/72.5.1343s
   WEBBER LS, 1986, J CHRON DIS, V39, P91, DOI 10.1016/0021-9681(86)90065-2
   Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132
NR 47
TC 73
Z9 88
U1 0
U2 7
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD FEB 15
PY 2005
VL 105
IS 2
BP 208
EP 214
DI 10.1016/j.jada.2004.11.026
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 893QA
UT WOS:000226733100009
PM 15668676
DA 2025-04-28
ER

PT J
AU Murase, T
   Haramizu, S
   Shimotoyodome, A
   Nagasawa, A
   Tokimitsu, I
AF Murase, T
   Haramizu, S
   Shimotoyodome, A
   Nagasawa, A
   Tokimitsu, I
TI Green tea extract improves endurance capacity and increases muscle lipid oxidation in mice
SO AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
LA English
DT Article
DE catechins; epigallocatechin gallate; lipid metabolism; swimming
ID chain fatty-acids; skeletal-muscle; insulin sensitivity; caffeine ingestion; n-acetylcysteine; free-radicals; exercise; metabolism; fatigue; obesity
AB Green tea contains a high level of polyphenolic compounds known as catechins. We investigated the effects of green tea extract (GTE), which is rich in catechins, on endurance capacity, energy metabolism, and fat oxidation in BALB/c mice over a 10-wk period. Swimming times to exhaustion for mice fed 0.2-0.5% (wt/wt) GTE were prolonged by 8-24%. The effects were dose dependent and accompanied by lower respiratory quotients and higher rates of fat oxidation as determined by indirect calorimetry. In addition, feeding with GTE increased the level of beta-oxidation activity in skeletal muscle. Plasma lactate concentrations in mice fed GTE were significantly decreased after exercise, concomitant with increases in free fatty acid concentrations in plasma, suggesting an increased lipid use as an energy source in GTE-fed mice. Epigallocatechin gallate (EGCG), a major component of tea catechins, also enhanced endurance capacity, suggesting that the endurance-improving effects of GTE were mediated, at least in part, by EGCG. The beta-oxidation activity and the level of fatty acid translocase/CD36 mRNA in the muscle was higher in GTE-fed mice compared with control mice. These results indicate that GTE are beneficial for improving endurance capacity and support the hypothesis that the stimulation of fatty acid use is a promising strategy for improving endurance capacity.
C1 Kao Corp, Biol Sci Labs, Ichikai, Tochigi 3213497, Japan.
C3 KAO Corporation
RP Kao Corp, Biol Sci Labs, 2606 Akabane, Ichikai, Tochigi 3213497, Japan.
EM murase.takatoshi@kao.co.jp
CR ALESSIO HM, 1993, MED SCI SPORT EXER, V25, P218, DOI 10.1249/00005768-199302000-00010
   BARCLAY JK, 1991, CAN J PHYSIOL PHARM, V69, P279, DOI 10.1139/y91-043
   Chyu KY, 2004, CIRCULATION, V109, P2448, DOI 10.1161/01.CIR.0000128034.70732.C2
   Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200
   COLLOMP K, 1991, INT J SPORTS MED, V12, P439, DOI 10.1055/s-2007-1024710
   Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577
   COSTILL DL, 1978, MED SCI SPORT EXER, V10, P155
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   GRAHAM TE, 1995, J APPL PHYSIOL, V78, P867, DOI 10.1152/jappl.1995.78.3.867
   Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638
   Hawley JA, 1998, SPORTS MED, V25, P241, DOI 10.2165/00007256-199825040-00003
   Horowitz JF, 2000, AM J CLIN NUTR, V72, P558S, DOI 10.1093/ajcn/72.2.558S
   Howlett RA, 2003, J APPL PHYSIOL, V94, P1682, DOI 10.1152/japplphysiol.00556.2002
   Ibrahimi A, 2002, CURR OPIN CLIN NUTR, V5, P139, DOI 10.1097/00075197-200203000-00004
   Ishihara K, 2000, J NUTR, V130, P2990, DOI 10.1093/jn/130.12.2990
   IVY JL, 1979, MED SCI SPORT EXER, V11, P6
   Jeukendrup AE, 1998, INT J SPORTS MED, V19, P371, DOI 10.1055/s-2007-971932
   Jeukendrup AE, 1998, INT J SPORTS MED, V19, P293, DOI 10.1055/s-2007-971921
   Kim KM, 1998, J NUTR, V128, P1978, DOI 10.1093/jn/128.11.1978
   Kim KM, 1997, BIOSCI BIOTECH BIOCH, V61, P1718, DOI 10.1271/bbb.61.1718
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Lee HJ, 2002, BIOCHEM BIOPH RES CO, V296, P293, DOI 10.1016/S0006-291X(02)00822-7
   LEIJTEN PAA, 1984, J PHYSIOL-LONDON, V357, P327, DOI 10.1113/jphysiol.1984.sp015502
   LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X
   Matsumoto K, 1996, J APPL PHYSIOL, V81, P1843, DOI 10.1152/jappl.1996.81.4.1843
   Mikami Y, 2002, J NEUROSURG, V97, P142, DOI 10.3171/spi.2002.97.1.0142
   Miller Y D, 2004, J SCI MED SPORT, V7, P52, DOI 10.1016/S1440-2440(04)80278-0
   Miura Y, 2001, J NUTR, V131, P27, DOI 10.1093/jn/131.1.27
   Mizunoya W, 2002, BIOSCI BIOTECH BIOCH, V66, P1133, DOI 10.1271/bbb.66.1133
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   NOVELLI GP, 1990, FREE RADICAL BIO MED, V8, P9, DOI 10.1016/0891-5849(90)90138-9
   REID MB, 1994, J CLIN INVEST, V94, P2468, DOI 10.1172/JCI117615
   REID MB, 1992, J APPL PHYSIOL, V73, P1797, DOI 10.1152/jappl.1992.73.5.1797
   RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9
   Ryan DH, 2003, INT J CLIN PRACT, V0, P28
   Schoonjans K, 1996, J LIPID RES, V37, P907
   SHINDOH C, 1990, J APPL PHYSIOL, V68, P2107, DOI 10.1152/jappl.1990.68.5.2107
   Shiota S, 1999, BIOL PHARM BULL, V22, P1388, DOI 10.1248/bpb.22.1388
   SINGH H, 1994, J BIOL CHEM, V269, P9514
   Stremmel W, 2001, LIPIDS, V36, P981, DOI 10.1007/s11745-001-0809-2
   Terada S, 2002, BIOCHEM BIOPH RES CO, V296, P350, DOI 10.1016/S0006-291X(02)00881-1
   Tunstall RJ, 2002, AM J PHYSIOL-ENDOC M, V283, PE66, DOI 10.1152/ajpendo.00475.2001
   Valet P, 2002, J LIPID RES, V43, P835
   Viña J, 2000, IUBMB LIFE, V50, P271, DOI 10.1080/15216540051080994
   Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294
   Willett WC, 1999, NEW ENGL J MED, V341, P427, DOI 10.1056/NEJM199908053410607
   YANG CS, 1993, J NATL CANCER I, V85, P1038, DOI 10.1093/jnci/85.13.1038
   ZHANG Y, 1990, J PHARMACOL EXP THER, V254, P757
NR 49
TC 176
Z9 188
U1 1
U2 34
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6119
EI 1522-1490
J9 AM J PHYSIOL-REG I
JI Am. J. Physiol.-Regul. Integr. Comp. Physiol.
PD MAR 15
PY 2005
VL 288
IS 3
BP R708
EP R715
DI 10.1152/ajpregu.00693.2004
PG 8
WC Physiology
SC Physiology
GA 895AJ
UT WOS:000226832800023
PM 15563575
DA 2025-04-28
ER

PT J
AU Kubo, K
   Kiyose, C
   Ogino, S
   Saito, M
AF Kubo, K
   Kiyose, C
   Ogino, S
   Saito, M
TI Suppressive effect of Citrus aurantium against body fat accumulation and its safety
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE Citrus aurantium; synephrine; dietary supplement; body fat accumulation; safety
ID human beta-3-adrenergic receptor; molecular-cloning; down-regulation; adipose-tissue; synephrine; octopamine; extracts; obesity; plants; white
AB A large number of so-called diet foods containing Citrus aurantium (CA) and its active constituent, synephrine, for suppressing body fat accumulation are currently on the market. However, only one human study has demonstrated the efficacy of CA, and its potential cardiotoxicity has been reported in a rat study. Therefore, we investigated the safety of CA and its suppressive effect against body fat accumulation in rats. High-fat (20% (w/w)) diets containing CA (synephrine content, 6.4%) at 0, 40, 200, 1,000, and 5,000 mg/kg diet were fed to rats ad libitum for 79 days. For dieting, the recommended daily intake of CA in many dietary supplements ranges from 100 to 1,000 mg/day, and the amount used in this experiment was approximately equivalent to 40 and/or 200 mg/kg diet. In the 5,000 mg/kg CA group, the adrenaline and dopamine concentrations in plasma were significantly higher, perirenal fat pad weight was significantly lower, and body weight tended to be lower than in the control group. Although no abnormalities of serum clinical and biochemical parameters were observed except for adrenaline and dopamine, and also no histopathological abnormalities were evident in the heart, heart weight in the 5,000 mg/kg CA group was significantly lower than in the control group. Therefore, it is necessary to examine more precisely the potential cardiotoxicity caused by excess intake of CA. Particularly, the elucidation of influences of the simultaneous intake of CA and some stimulants, such as caffeine, awaits further characterization.
C1 Natl Inst Hlth & Nutr, Div Food Sci, Inc Adm Agcy, Shinjuku Ku, Tokyo 1628636, Japan.
C3 National Institute of Health & Nutrition - Japan
RP Saito, M (corresponding author), Natl Inst Hlth & Nutr, Div Food Sci, Inc Adm Agcy, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628636, Japan.
EM msaito@nih.go.jp
CR ATWATER WO, 1910, USDA FARMERS B, V142, P48
   BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297
   Calapai G, 1999, FITOTERAPIA, V70, P586, DOI 10.1016/S0367-326X(99)00093-3
   Carpéné C, 1999, N-S ARCH PHARMACOL, V359, P310, DOI 10.1007/PL00005357
   Carpéné C, 1998, ANN NY ACAD SCI, V839, P186, DOI 10.1111/j.1749-6632.1998.tb10756.x
   Colker CM, 1999, CURR THER RES CLIN E, V60, P145, DOI 10.1016/S0011-393X(00)88523-9
   DUNCAN DB, 1957, BIOMETRICS, V13, P164, DOI 10.2307/2527799
   EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461
   GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895
   IBRAHIM KE, 1985, J NEUROCHEM, V44, P1862, DOI 10.1111/j.1471-4159.1985.tb07180.x
   KUSU F, 1995, CHEM PHARM BULL, V43, P1158, DOI 10.1248/cpb.43.1158
   LAFONTAN M, 1993, J LIPID RES, V34, P1057
   LELIAS JM, 1993, FEBS LETT, V324, P127, DOI 10.1016/0014-5793(93)81377-C
   Marcus DM, 2003, SCIENCE, V301, P1669
   Moro CO, 2000, FITOTERAPIA, V71, PS73, DOI 10.1016/S0367-326X(00)00177-5
   MUZZIN P, 1991, J BIOL CHEM, V266, P24053
   NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x
   Nykamp DL, 2004, ANN PHARMACOTHER, V38, P812, DOI 10.1345/aph.1D473
   Park JH, 1998, GEN COMP ENDOCR, V110, P88, DOI 10.1006/gcen.1997.7053
   Parra AL, 2001, PHYTOMEDICINE, V8, P395, DOI 10.1078/0944-7113-00044
   REEVES PG, 1993, J NUTR, V123, P1939, DOI 10.1093/jn/123.11.1939
   Shirai Y, 2003, J CLIN BIOCHEM NUTR, V33, P53
   STEWART I, 1964, J BIOL CHEM, V239, P930
   WHEATLEY AM, 1985, J MOL CELL CARDIOL, V17, P349, DOI 10.1016/S0022-2828(85)80134-6
   WHEATON TA, 1970, LLOYD, V33, P244
NR 25
TC 9
Z9 9
U1 0
U2 4
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602-8566, JAPAN
SN 0912-0009
EI 1880-5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD JUN 15
PY 2005
VL 36
IS 1
BP 11
EP 17
DI 10.3164/jcbn.36.11
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 916QV
UT WOS:000228401600002
DA 2025-04-28
ER

PT J
AU Diepvens, K
   Kovacs, EMR
   Nijs, IMT
   Vogels, N
   Westerterp-Plantenga, MS
AF Diepvens, K
   Kovacs, EMR
   Nijs, IMT
   Vogels, N
   Westerterp-Plantenga, MS
TI Effect of green tea on resting energy expenditure and substrate oxidation during weight loss in overweight females
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Article
DE green tea; weight loss; resting energy expenditure; substrate oxidation
ID total-body water; catechin-polyphenols; caffeine consumption; semisolid meal; metabolic-rate; guar gum; maintenance; fat; thermogenesis; appetite
AB We assessed the effect of ingestion of green tea (GT) extract along with a low-energy diet (LED) on resting energy expenditure (REE), substrate oxidation and body weight as GT has been shown to increase energy expenditure and fat oxidation in the short term in both animals and people. Forty-six overweight women (BMI 27 center dot 6 (sd 1 center dot 8) kg/m(2)) were fed in energy balance from day 1 to day 3, followed by a LED with GT (1125 mg tea catechins +225 mg caffeine/d) or placebo (PLAC) from day 4 to day 87. Caffeine intake was standardised to 300 mg/d. Energy expenditure was measured on days 4 and 32. Reductions in weight (4 center dot 19 (sd 2 center dot 0) kg PLAC, 4 center dot 21 (sd 2 center dot 7) kg GT), BMI, waist:hip ratio, fat mass and fat-free mass were not statistically different between treatments. REE as a function of fat-free mass and fat mass was significantly reduced over 32 d in the PLAC group (P < 0 center dot 05) but not in the GT group. Dietary restraint increased over time (P < 0 center dot 001) in both groups, whereas disinhibition and general hunger decreased (P < 0 center dot 05). The GT group became more hungry over time and less thirsty, and showed increased prospective food consumption compared with PLAC (P < 0 center dot 05). Taken together, the ingestion of GT along with a LED had no additional benefit for any measures of body weight or body composition. Although the decrease in REE as a function of fat-free mass and fat mass was not significant with GT treatment, whereas it was with PLAC treatment, no significant effect of treatment over time was seen, suggesting that a robust limitation of REE reduction during a LED was not achieved by GT.
C1 Maastricht Univ, Maastricht, Netherlands.
   Unilever Res Labs, Unilever Food & Hlth Res Inst, Vlaardingen, Netherlands.
C3 Maastricht University; Unilever
RP Maastricht Univ, Maastricht, Netherlands.
EM K.Diepvens@HB.Unimaas.NL
CR ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Astrup A, 1999, AM J CLIN NUTR, V69, P1117
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   Chantre P, 2002, PHYTOMEDICINE, V9, P3, DOI 10.1078/0944-7113-00078
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Hase T, 2001, JOURNAL OF OLEO SCIENCE, V50, P599, DOI 10.5650/jos.50.599
   Hodgson JM, 1999, J HYPERTENS, V17, P457, DOI 10.1097/00004872-199917040-00002
   Hulshof KFAM, 2003, EUR J CLIN NUTR, V57, P128, DOI 10.1038/sj.ejcn.1601503
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   Kovacs EMR, 2002, EUR J CLIN NUTR, V56, P771, DOI 10.1038/sj.ejcn.1601407
   Kovacs EMR, 2001, INT J OBESITY, V25, P307, DOI 10.1038/sj.ijo.0801546
   LEJEUNE MPG, 2003, BR J NUTR, V90, P1
   LICHTENBELT WDV, 1994, BRIT J NUTR, V72, P491, DOI 10.1079/BJN19940053
   Menozzi R, 2000, BRIT J NUTR, V84, P515
   Nagao T, 2005, AM J CLIN NUTR, V81, P122
   Nagao T, 2001, JOURNAL OF OLEO SCIENCE, V50, P717
   Pasman WJ, 1999, METABOLISM, V48, P15, DOI 10.1016/S0026-0495(99)90004-5
   Pasman WJ, 1999, OBES RES, V7, P43, DOI 10.1002/j.1550-8528.1999.tb00389.x
   RAVUSSIN E, 1992, AM J CLIN NUTR, V55, P242
   RAVUSSIN E, 1988, NEW ENGL J MED, V318, P467, DOI 10.1056/NEJM198802253180802
   Rayner DV, 2001, J MOL MED, V79, P8, DOI 10.1007/s001090100198
   SCHOELLER DA, 1980, AM J CLIN NUTR, V33, P2686, DOI 10.1093/ajcn/33.12.2686
   Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   Stunkard AJ, 1996, AM J MED, V100, P230, DOI 10.1016/S0002-9343(97)89464-8
   Trayhurn P, 1999, INT J OBESITY, V23, P22, DOI 10.1038/sj.ijo.0800791
   Trayhurn P, 2001, INT J OBESITY, V25, PS26, DOI 10.1038/sj.ijo.0801692
   TSUCHIDA T, 2002, PROGR MED, V22, P2189
   van Boxtel MPJ, 2003, PHARMACOL BIOCHEM BE, V75, P921, DOI 10.1016/S0091-3057(03)00171-0
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Weisburger JH, 1997, CANCER LETT, V114, P315, DOI 10.1016/S0304-3835(97)04691-0
   WESTERTERP KR, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00007.x
   WESTERTERP KR, 1995, BRIT J NUTR, V73, P337, DOI 10.1079/BJN19950037
   Westerterp-Plantenga MS, 1998, INT J OBESITY, V22, P1, DOI 10.1038/sj.ijo.0800536
   WHO Consultation, 2000, WHO TECH REP SER, V894, P1
   Yoshioka M, 2001, BRIT J NUTR, V85, P203, DOI 10.1079/BJN2000224
NR 44
TC 102
Z9 111
U1 0
U2 28
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD DEC 15
PY 2005
VL 94
IS 6
BP 1026
EP 1034
DI 10.1079/BJN20051580
PG 9
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 992WC
UT WOS:000233913700024
PM 16351782
DA 2025-04-28
ER

PT J
AU Lee, S
   Hudson, R
   Kilpatrick, K
   Graham, TE
   Ross, R
AF Lee, S
   Hudson, R
   Kilpatrick, K
   Graham, TE
   Ross, R
TI Caffeine ingestion is associated with reductions in glucose uptake independent of obesity and type 2 diabetes before and after exercise training
SO DIABETES CARE
LA English
DT Article
ID insulin sensitivity; tolerance test; weight-loss; coffee consumption; induced impairment; controlled-trial; skeletal-muscle; men; resistance; humans
AB OBJECTIVE - We investigated the effect of caffeine ingestion oil insulin sensitivity in sedentary lean men (n = 8) and obese men with (n = 7) and without (11 = 8) type 2 diabetes. We also examined whether chronic exercise influences the relationship between caffeine and insulin sensitivity in these individuals. RESEARCH DESIGN AND METHODS - Subjects underwent two hyperinsulinemic-euglycemic clamp procedures, caffeine (5 mg/kg body wt) and placebo, in a double-blind, randomized manner before and after a 3-month aerobic exercise program. Body composition was measured by magnetic resonance imaging. RESULTS - At baseline, caffeine ingestion was associated with a significant reduction (P < 0.05) in insulin sensitivity by a similar magnitude in the lean (33%), obese (33%), and type 2 diabetic (37%) groups in comparison with placebo. After exercise training, caffeine ingestion was Still associated with a reduction (P < 0.05) in insulin sensitivity by a similar magnitude in the lean (23%), obese (26%), and type 2 diabetic (36%) groups in comparison with placebo, Exercise was not associated with a significant increase in insulin sensitivity in either the caffeine or placebo trials, independent of group (P > 0.10). CONCLUSIONS - Caffeine consumption is associated with a substantial reduction in insulin-mediated glucose uptake independent of obesity, type 2 diabetes, and chronic exercise.
C1 Queens Univ, Sch Phys & Hlth Educ, Kingston, ON K7L 3N6, Canada.
   Queens Univ, Div Endocrinol & Metab, Dept Med, Kingston, ON, Canada.
   Queens Univ, Div Geriatr, Dept Med, Kingston, ON, Canada.
   Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens University - Canada; University of Guelph
RP Queens Univ, Sch Phys & Hlth Educ, Kingston, ON K7L 3N6, Canada.
EM rossr@post.queensu.ca
CR Arnaud MJ, 1993, CAFFEINE COFFEE HLTH, V0, P43
   BARON AD, 1987, J CLIN ENDOCR METAB, V64, P889, DOI 10.1210/jcem-64-5-889
   BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311
   Brown J, 2001, AM J EPIDEMIOL, V153, P815, DOI 10.1093/aje/153.8.815
   Cuff DJ, 2003, DIABETES CARE, V26, P2977, DOI 10.2337/diacare.26.11.2977
   DEIBERT DC, 1980, J CLIN INVEST, V65, P717, DOI 10.1172/JCI109718
   Dengel DR, 1996, J APPL PHYSIOL, V81, P318, DOI 10.1152/jappl.1996.81.1.318
   Duncan GE, 2003, DIABETES CARE, V26, P557, DOI 10.2337/diacare.26.3.557
   Graham TE, 2001, CAN J PHYSIOL PHARM, V79, P559, DOI 10.1139/cjpp-79-7-559
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Han DH, 1998, DIABETES, V47, P1671, DOI 10.2337/diabetes.47.11.1671
   Harland BF, 2000, NUTRITION, V16, P522, DOI 10.1016/S0899-9007(00)00369-5
   Harris J, 1919, BIOMETRIC STUDY BASA, V0, P0
   HUGHES VA, 1993, AM J PHYSIOL, V264, PE855, DOI 10.1152/ajpendo.1993.264.6.E855
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   Lopez-Ridaura R, 2004, DIABETES CARE, V27, P134, DOI 10.2337/diacare.27.1.134
   MILES J, 1983, J LIPID RES, V24, P96
   NUUTILA P, 1995, DIABETES, V44, P31, DOI 10.2337/diabetes.44.1.31
   Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804
   Petrie HJ, 2004, AM J CLIN NUTR, V80, P22
   Pizziol A, 1998, EUR J CLIN NUTR, V52, P846, DOI 10.1038/sj.ejcn.1600657
   Rice B, 1999, DIABETES CARE, V22, P684, DOI 10.2337/diacare.22.5.684
   Robinson LE, 2004, J NUTR, V134, P2528, DOI 10.1093/jn/134.10.2528
   Rodríguez-Morán M, 2003, DIABETES CARE, V26, P1147, DOI 10.2337/diacare.26.4.1147
   Ross R, 2004, OBES RES, V12, P789, DOI 10.1038/oby.2004.95
   ROSS R, 1992, J APPL PHYSIOL, V72, P787, DOI 10.1152/jappl.1992.72.2.787
   Ross R, 2000, EXERC SPORT SCI REV, V28, P165
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402
   Shearer J, 2003, J NUTR, V133, P3529, DOI 10.1093/jn/133.11.3529
   Snyder WS, 1974, REPORT TASK GROUP RE, V0, P0
   Thong FSL, 2002, J APPL PHYSIOL, V92, P2347, DOI 10.1152/japplphysiol.01229.2001
   Thong FSL, 2002, DIABETES, V51, P583, DOI 10.2337/diabetes.51.3.583
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   VERGAUWEN L, 1994, J CLIN INVEST, V93, P974, DOI 10.1172/JCI117104
NR 35
TC 75
Z9 80
U1 0
U2 19
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD MAR 15
PY 2005
VL 28
IS 3
BP 566
EP 572
DI 10.2337/diacare.28.3.566
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 903ME
UT WOS:000227429200011
PM 15735189
DA 2025-04-28
ER

PT J
AU Wolfram, S
   Raederstorff, D
   Wang, Y
   Teixeira, SR
   Elste, V
   Weber, P
AF Wolfram, S
   Raederstorff, D
   Wang, Y
   Teixeira, SR
   Elste, V
   Weber, P
TI TEAVIGO™ (epigallocatechin gallate) supplementation prevents obesity in rodents by reducing adipose tissue mass
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Article
DE TEAVIGO (TM); epigallocatechin gallate; obesity; adipose tissue; rodents; gene expression; green tea; catechin
ID green tea; catechin-polyphenols; diabetes-mellitus; fat oxidation; in-vitro; rats; inhibition; prevalence; absorption; caffeine
AB Background: This study investigated the antiobesity effects of TEAVIGO(TM), a product providing the most abundant green tea catechin, epigallocatechin gallate ( EGCG), in a pure form. Two models of diet-induced obesity and an in vitro adipocyte differentiation assay were employed. Methods: Prevention and regression of diet-induced obesity by dietary supplementation with EGCG was studied in C57BL/6J mice and Sprague-Dawley rats, respectively. Expression of genes regulating lipid metabolism was assessed in adipose tissue. The effects of EGCG on adipocyte differentiation were investigated in vitro. Results: In C57BL/6J mice, EGCG supplementation prevented diet-induced increases in body weight and in fed state plasma levels of glucose, triglycerides, and leptin. EGCG decreased subcutaneous and epididymal adipose tissue weights. Supplementation of EGCG reversed the established obesity in Sprague-Dawley rats. Fatty acid synthase and acetyl-CoA carboxylase-1 mRNA levels were markedly decreased in adipose tissue of EGCG-supplemented mice. EGCG dose dependently inhibited adipocyte differentiation in vitro. Conclusion: This study shows for the first time that supplementation with the most abundant green tea polyphenol, EGCG, abolishes diet-induced obesity. This effect is at least partly mediated via a direct influence on adipose tissue. Thus, dietary supplementation with EGCG should be considered as a valuable natural treatment option for obesity. Copyright (C) 2005 S. Karger AG, Basel.
C1 DSM Nutr Prod Ltd, Dept Human Nutr & Hlth, CH-4002 Basel, Switzerland.
C3 DSM NV
RP Wolfram, S (corresponding author), DSM Nutr Prod Ltd, Dept Human Nutr & Hlth, Bldg 205-020,POB 3255, CH-4002 Basel, Switzerland.
EM swen.wolfram@dsm.com
CR Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100
   Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530
   Chen LS, 1997, DRUG METAB DISPOS, V25, P1045
   Dulloo AG, 2000, INT J OBESITY, V24, P252, DOI 10.1038/sj.ijo.0801101
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723
   Goran MI, 2003, J CLIN ENDOCR METAB, V88, P1417, DOI 10.1210/jc.2002-021442
   HARA Y, 1990, AGR BIOL CHEM TOKYO, V54, P1939, DOI 10.1080/00021369.1990.10870239
   Juhel C, 2000, J NUTR BIOCHEM, V11, P45, DOI 10.1016/S0955-2863(99)00070-4
   Jung YD, 2001, INT J EXP PATHOL, V82, P309, DOI 10.1046/j.1365-2613.2001.00205.x
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164
   Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832
   MATSUMOTO N, 1993, BIOSCI BIOTECH BIOCH, V57, P525, DOI 10.1271/bbb.57.525
   Murase T, 2002, INT J OBESITY, V26, P1459, DOI 10.1038/sj.ijo.0802141
   Ntambi JM, 2002, P NATL ACAD SCI USA, V99, P11482, DOI 10.1073/pnas.132384699
   Osada K, 2001, COMP BIOCHEM PHYS C, V128, P153, DOI 10.1016/S1532-0456(00)00192-7
   Raederstorff DG, 2003, J NUTR BIOCHEM, V14, P326, DOI 10.1016/S0955-2863(03)00054-8
   Rios MS, 1998, EUR J CLIN INVEST, V28, P14
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Sano M, 2001, ANALYST, V126, P816, DOI 10.1039/b102541b
   Sartippour MR, 2002, J NUTR, V132, P2307, DOI 10.1093/jn/132.8.2307
   Seidell JC, 2002, J ENDOCRINOL INVEST, V25, P816, DOI 10.1007/BF03344045
   Sheard NF, 2003, NUTR REV, V61, P76, DOI 10.1301/nr.2003.febr.76-79
   Shimizu M, 2000, BIOFACTORS, V13, P61, DOI 10.1002/biof.5520130111
   Sueoka N, 2001, ANN NY ACAD SCI, V928, P274
   Ullmann U, 2003, J INT MED RES, V31, P88, DOI 10.1177/147323000303100205
   Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355
NR 28
TC 173
Z9 197
U1 1
U2 23
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PD JUN 15
PY 2005
VL 49
IS 1
BP 54
EP 63
DI 10.1159/000084178
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 920DZ
UT WOS:000228670900009
PM 15735368
DA 2025-04-28
ER

PT J
AU Schulze, MB
   Hu, FB
AF Schulze, MB
   Hu, FB
TI Primary prevention of diabetes: What can be done and how much can be prevented?
SO ANNUAL REVIEW OF PUBLIC HEALTH
LA English
DT Review; Book Chapter
ID impaired glucose-tolerance; coronary-heart-disease; time physical-activity; body-fat distribution; dietary fiber intake; moderate alcohol-consumption; fructose corn syrup; whole-grain intake; 20-year follow-up; aged finnish men
AB Although it is widely believed that type 2 diabetes mellitus is the result of a complex interplay between genetic and environmental factors, compelling evidence from epidemiologic studies indicates that the current worldwide diabetes epidemic is largely due to changes in diet and lifestyle. Prospective cohort studies and randomized clinical trials have demonstrated that type 2 diabetes can be prevented largely through moderate diet and lifestyle modifications. Excess adiposity is the most important risk factor for diabetes, and thus, maintaining a healthy body weight and avoiding weight gain during adulthood is the cornerstone of diabetes prevention. Increasing physical activity and reducing sedentary behaviors such as prolonged TV watching are important both for maintaining body weight and improving insulin sensitivity. There is increasing evidence that the quality of fat and carbohydrate plays a more important role than does the quantity, and thus, public health strategies should emphasize replacing saturated and trans fats with unsaturated fats and replacing refined grain products with whole grains. Recent studies have also suggested a potential role for coffee, dairy, nuts, magnesium, and calcium in preventing diabetes. Overall, a healthy diet, together with regular physical activity, maintenance of a healthy weight, moderate alcohol consumption, and avoidance of sedentary behaviors and smoking, could nearly eliminate type 2 diabetes. However, there is still a wide gap between what we know and what we practice in the field of public health; how to narrow that gap remains a major public health challenge.
C1 Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital; Harvard University; Harvard Medical School
RP Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
EM mschulze@mail.dife.de; frank.hu@channing.harvard.edu
CR Ajani UA, 2000, ARCH INTERN MED, V160, P1025, DOI 10.1001/archinte.160.7.1025
   Unknown -, 2003, WORLD HLTH REP 2002, V0, P0
   BALKAU B, 1985, AM J EPIDEMIOL, V122, P594, DOI 10.1093/oxfordjournals.aje.a114139
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   Buchanan TA, 2002, DIABETES, V51, P2796, DOI 10.2337/diabetes.51.9.2796
   BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499
   Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158
   Carlsson S, 2003, DIABETES CARE, V26, P2785, DOI 10.2337/diacare.26.10.2785
   Chandalia M, 2000, NEW ENGL J MED, V342, P1392, DOI 10.1056/NEJM200005113421903
   Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
   Christiansen E, 1997, DIABETES CARE, V20, P881, DOI 10.2337/diacare.20.5.881
   COLDITZ GA, 1992, AM J CLIN NUTR, V55, P1018, DOI 10.1093/ajcn/55.5.1018
   COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001
   COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288
   Conigrave KM, 2001, DIABETES, V50, P2390, DOI 10.2337/diabetes.50.10.2390
   Cordain L, 2000, METABOLISM, V49, P1473, DOI 10.1053/meta.2000.17672
   Davies MJ, 2002, JAMA-J AM MED ASSOC, V287, P2559, DOI 10.1001/jama.287.19.2559
   de Vegt F, 2002, DIABETES RES CLIN PR, V57, P53, DOI 10.1016/S0168-8227(02)00013-X
   Duncan GE, 2003, DIABETES CARE, V26, P557, DOI 10.2337/diacare.26.3.557
   Eliasson B, 1997, EUR J CLIN INVEST, V27, P450, DOI 10.1046/j.1365-2362.1997.1330680.x
   Eliasson M, 2004, J INTERN MED, V256, P101, DOI 10.1111/j.1365-2796.2004.01344.x
   FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437
   FESKENS EJM, 1995, DIABETES CARE, V18, P1104, DOI 10.2337/diacare.18.8.1104
   Field AE, 2004, OBES RES, V12, P267, DOI 10.1038/oby.2004.34
   Flanagan DEH, 2002, EUR J CLIN INVEST, V32, P187, DOI 10.1046/j.1365-2362.2002.00970.x
   Ford ES, 2001, PREV MED, V32, P33, DOI 10.1006/pmed.2000.0772
   Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207
   Freeman DJ, 2001, CIRCULATION, V103, P357
   FUKAGAWA NK, 1990, AM J CLIN NUTR, V52, P524, DOI 10.1093/ajcn/52.3.524
   Fung TT, 2002, AM J CLIN NUTR, V76, P535, DOI 10.1093/ajcn/76.3.535
   FUNG TT, 2004, IN PRESS ARCH INTERN, V0, P0
   GOHDES D, 1993, DIABETES CARE, V16, P239, DOI 10.2337/diacare.16.1.239
   GURWITZ JH, 1994, J AM GERIATR SOC, V42, P1235, DOI 10.1111/j.1532-5415.1994.tb06503.x
   Haapanen N, 1997, INT J EPIDEMIOL, V26, P739, DOI 10.1093/ije/26.4.739
   Harding AH, 2004, AM J EPIDEMIOL, V159, P73, DOI 10.1093/aje/kwh004
   HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302
   Herman WH, 2003, DIABETES CARE, V26, P36
   HODGE AM, 1993, AM J EPIDEMIOL, V137, P178, DOI 10.1093/oxfordjournals.aje.a116658
   HODGE AM, 1994, INT J OBESITY, V18, P419
   HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733
   Howard AA, 2004, ANN INTERN MED, V140, P211, DOI 10.7326/0003-4819-140-6-200403160-00011
   Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492
   Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433
   Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547
   Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785
   Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542
   Hu G, 2004, ARCH INTERN MED, V164, P892, DOI 10.1001/archinte.164.8.892
   Hu G, 2003, DIABETOLOGIA, V46, P322, DOI 10.1007/s00125-003-1031-x
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   Jéquier E, 2002, AM J MED, V113, P41, DOI 10.1016/S0002-9343(01)00991-3
   Jiang R, 2004, JAMA-J AM MED ASSOC, V291, P711, DOI 10.1001/jama.291.6.711
   Jiang R, 2004, AM J CLIN NUTR, V79, P70
   Jiang R, 2002, JAMA-J AM MED ASSOC, V288, P2554, DOI 10.1001/jama.288.20.2554
   Juntunen KS, 2003, AM J CLIN NUTR, V77, P385
   Kao WHL, 1999, ARCH INTERN MED, V159, P2151, DOI 10.1001/archinte.159.18.2151
   Kao WHL, 2001, AM J EPIDEMIOL, V154, P748, DOI 10.1093/aje/154.8.748
   Kawakami N, 1997, AM J EPIDEMIOL, V145, P103
   KAYE SA, 1991, J CLIN EPIDEMIOL, V44, P329, DOI 10.1016/0895-4356(91)90044-A
   Keenan Joseph M, 2002, J FAM PRACT, V51, P369
   Klonoff DC, 2000, DIABETES CARE, V23, P390, DOI 10.2337/diacare.23.3.390
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/nejmoa012512
   Koh-Banerjee P, 2004, AM J EPIDEMIOL, V159, P1150, DOI 10.1093/aje/kwh167
   Kriska AM, 2003, AM J EPIDEMIOL, V158, P669, DOI 10.1093/aje/kwg191
   Lee DH, 2004, DIABETOLOGIA, V47, P185, DOI 10.1007/s00125-003-1307-1
   Lichtenstein AH, 2003, ATHEROSCLEROSIS, V171, P97, DOI 10.1016/j.atherosclerosis.2003.07.005
   Lichtenstein AH, 2000, ATHEROSCLEROSIS, V150, P227, DOI 10.1016/S0021-9150(99)00504-3
   Lindholm LH, 2002, J HYPERTENS, V20, P1879, DOI 10.1097/00004872-200209000-00035
   Liu SM, 2002, J AM COLL NUTR, V21, P298, DOI 10.1080/07315724.2002.10719227
   Liu SM, 2000, AM J PUBLIC HEALTH, V90, P1409, DOI 10.2105/AJPH.90.9.1409
   Lopez-Ridaura R, 2004, DIABETES CARE, V27, P134, DOI 10.2337/diacare.27.1.134
   Louheranta AM, 1999, METABOLISM, V48, P870, DOI 10.1016/S0026-0495(99)90221-4
   Lovejoy JC, 2002, DIABETES CARE, V25, P1283, DOI 10.2337/diacare.25.8.1283
   Lu WQ, 2003, METABOLISM, V52, P129, DOI 10.1053/meta.2003.50020
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   LUNDGREN H, 1989, INT J OBESITY, V13, P413
   MANSON JE, 1994, AM J PREV MED, V10, P172, DOI 10.1016/S0749-3797(18)30615-9
   MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B
   MARSHALL JA, 1994, DIABETES CARE, V17, P50, DOI 10.2337/diacare.17.1.50
   Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669
   MCPHILLIPS JB, 1990, AM J EPIDEMIOL, V131, P443, DOI 10.1093/oxfordjournals.aje.a115519
   MEDALIE JH, 1975, ARCH INTERN MED, V135, P811, DOI 10.1001/archinte.135.6.811
   Meyer KA, 2000, AM J CLIN NUTR, V71, P921
   Meyer KA, 2001, DIABETES CARE, V24, P1528, DOI 10.2337/diacare.24.9.1528
   MONTERROSA AE, 1995, DIABETES CARE, V18, P448, DOI 10.2337/diacare.18.4.448
   Montonen J, 2003, AM J CLIN NUTR, V77, P622, DOI 10.1093/ajcn/77.3.622
   Nakanishi N, 2003, DIABETES CARE, V26, P48, DOI 10.2337/diacare.26.1.48
   NEEL JV, 1962, AM J HUM GENET, V14, P353
   OHLSON LO, 1988, DIABETOLOGIA, V31, P798
   OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055
   Okada K, 2000, DIABETIC MED, V17, P53, DOI 10.1046/j.1464-5491.2000.00229.x
   PAFFENBARGER RS, 1973, AM J EPIDEMIOL, V97, P314, DOI 10.1093/oxfordjournals.aje.a121511
   Palmer AJ, 2004, CLIN THER, V26, P304, DOI 10.1016/S0149-2918(04)90029-X
   Pan XR, 1997, DIABETES CARE, V20, P537, DOI 10.2337/diacare.20.4.537
   Paolisso G, 1997, AM J HYPERTENS, V10, P346, DOI 10.1016/S0895-7061(96)00342-1
   Parikh SJ, 2003, AM J CLIN NUTR, V77, P281, DOI 10.1093/ajcn/77.2.281
   Pereira MA, 2002, JAMA-J AM MED ASSOC, V287, P2081, DOI 10.1001/jama.287.16.2081
   Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848
   Pereira MA, 2001, PEDIATR CLIN N AM, V48, P969, DOI 10.1016/S0031-3955(05)70351-5
   Perry IJ, 2001, INT J EPIDEMIOL, V30, P554, DOI 10.1093/ije/30.3.554
   Petersen M, 2003, DIABETES CARE, V26, P917
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   Raben A, 2002, AM J CLIN NUTR, V76, P721, DOI 10.1093/ajcn/76.4.721
   RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211
   RIMM EB, 1995, BRIT MED J, V310, P555, DOI 10.1136/bmj.310.6979.555
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Sairenchi T, 2004, AM J EPIDEMIOL, V160, P158, DOI 10.1093/aje/kwh183
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545
   Salmerón J, 2001, AM J CLIN NUTR, V73, P1019
   Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927
   Schulze MB, 2004, AM J CLIN NUTR, V80, P348, DOI 10.1093/ajcn/80.2.348
   Schulze MB, 2003, DIABETOLOGIA, V46, P1465, DOI 10.1007/s00125-003-1220-7
   Sierksma A, 2004, DIABETES CARE, V27, P184, DOI 10.2337/diacare.27.1.184
   Slattery M L, 2000, SEMIN GASTROINTEST DIS, V11, P142
   Song Y, 2004, DIABETES CARE, V27, P2108, DOI 10.2337/diacare.27.9.2108
   Song YQ, 2004, DIABETES CARE, V27, P59, DOI 10.2337/diacare.27.1.59
   STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002
   Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103
   Steven J, 2002, DIABETES CARE, V25, P1715, DOI 10.2337/diacare.25.10.1715
   Stumvoll M, 2002, ANN MED, V34, P217, DOI 10.1080/713782132
   Sugimori H, 1998, J MED SYST, V22, P27, DOI 10.1023/A:1022650305109
   Summers LKM, 2002, DIABETOLOGIA, V45, P369, DOI 10.1007/s00125-001-0768-3
   THORBURN A, 1993, METABOLISM, V42, P780, DOI 10.1016/0026-0495(93)90249-N
   TORDOFF MG, 1990, AM J CLIN NUTR, V51, P963, DOI 10.1093/ajcn/51.6.963
   Tosiello L, 1996, ARCH INTERN MED, V156, P1143, DOI 10.1001/archinte.156.11.1143
   Tsumura K, 1999, DIABETES CARE, V22, P1432, DOI 10.2337/diacare.22.9.1432
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2003, EUR J EPIDEMIOL, V18, P1115
   van Dam RM, 2002, DIABETES CARE, V25, P417, DOI 10.2337/diacare.25.3.417
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008
   Vessby B, 2001, DIABETOLOGIA, V44, P312, DOI 10.1007/s001250051620
   Wannamethee SG, 2003, ARCH INTERN MED, V163, P1329, DOI 10.1001/archinte.163.11.1329
   Wannamethee SG, 2002, J EPIDEMIOL COMMUN H, V56, P542, DOI 10.1136/jech.56.7.542
   Wannamethee SG, 2001, DIABETES CARE, V24, P1590, DOI 10.2337/diacare.24.9.1590
   Wannamethee SG, 2000, ARCH INTERN MED, V160, P2108, DOI 10.1001/archinte.160.14.2108
   Watanabe M, 2002, DIABETES RES CLIN PR, V57, P191, DOI 10.1016/S0168-8227(02)00083-9
   Wei M, 2000, DIABETES CARE, V23, P18, DOI 10.2337/diacare.23.1.18
   Wei M, 1997, OBES RES, V5, P16, DOI 10.1002/j.1550-8528.1997.tb00278.x
   Weinstein AR, 2004, JAMA-J AM MED ASSOC, V292, P1188, DOI 10.1001/jama.292.10.1188
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Will JC, 2001, INT J EPIDEMIOL, V30, P540, DOI 10.1093/ije/30.3.540
   Willemsen R, 2002, NEUE RUNDSCH, V113, P9
   Wilson JG, 2003, AM J MED SCI, V325, P332, DOI 10.1097/00000441-200306000-00004
   WILSON PWF, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90532-2
   Yusuf S, 2001, JAMA-J AM MED ASSOC, V286, P1882, DOI 10.1001/jama.286.15.1882
   Zilkens RR, 2003, DIABETES CARE, V26, P608, DOI 10.2337/diacare.26.3.608
NR 152
TC 211
Z9 247
U1 2
U2 40
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0163-7525
EI 1545-2093
J9 ANNU REV PUBL HEALTH
JI Annu. Rev. Public Health
PD JUN 15
PY 2005
VL 26
IS 
BP 445
EP 467
DI 10.1146/annurev.publhealth.26.021304.144532
PG 23
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 924LY
UT WOS:000228981500020
PM 15760297
DA 2025-04-28
ER

PT J
AU Westerterp-Plantenga, MS
   Lejeune, MPGM
   Kovacs, EMR
AF Westerterp-Plantenga, MS
   Lejeune, MPGM
   Kovacs, EMR
TI Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation
SO OBESITY RESEARCH
LA English
DT Article
DE energy expenditure; fat oxidation; satiety; leptin; thermogenesis
ID follow-up; energy-expenditure; fat oxidation; double-blind; diet; ephedrine; protein; obesity; thermogenesis; carbohydrate
AB Objective: Investigation of the effect of a green tea-caffeine mixture on weight maintenance after body weight loss in moderately obese subjects in relation to habitual caffeine intake. Research Methods and Procedures: A randomized placebo-controlled double blind parallel trial in 76 overweight and moderately obese subjects, (BMI, 27.5 +/- 2.7 kg/m(2)) matched for sex, age, BMI, height, body mass, and habitual caffeine intake was conducted. A very low energy diet intervention during 4 weeks was followed by 3 months of weight maintenance (WM); during the WM period, the subjects received a green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine per day) or placebo. Results: Subjects lost 5.9 +/- 1.8 (SD) kg (7.0 +/- 2.1%) of body weight (p < 0.001). At baseline, satiety was positively, and in women, leptin was inversely, related to subjects' habitual caffeine consumption (p < 0.01). High caffeine consumers reduced weight, fat mass, and waist circumference more than low caffeine consumers; resting energy expenditure was reduced less and respiratory quotient was reduced more during weight loss (p < 0.01). In the low caffeine consumers, during WM, green tea still reduced body weight, waist, respiratory quotient and body fat, whereas resting energy expenditure was increased compared with a restoration of these variables with placebo (p < 0.01). In the high caffeine consumers, no effects of the green tea-caffeine mixture were observed during WM. Discussion: High caffeine intake was associated with weight loss through thermogenesis and fat oxidation and with suppressed leptin in women. In habitual low caffeine consumers, the green tea-caffeine mixture improved WM, partly through thermogenesis and fat oxidation.
C1 Maastricht Univ, Dept Human Biol, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University
RP Maastricht Univ, Dept Human Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
EM m.westerterp@hb.unimaas.nl
CR ARCIERO PJ, 2002, 49 ANN M AM COLL SPO, V0, P0
   ASTRUP A, 1992, INT J OBESITY, V16, P269
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   BORCHARDT RT, 1975, J MED CHEM, V18, P120, DOI 10.1021/jm00235a030
   BRACCO D, 1995, AM J PHYSIOL, V0, PE671
   DULLOO AG, 1989, AM J CLIN NUTR, V49, P44, DOI 10.1093/ajcn/49.1.44
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   DULLOO AG, 1992, METABOLISM, V41, P1233, DOI 10.1016/0026-0495(92)90015-3
   Ekelund U, 2000, INT J SPORTS MED, V21, P586, DOI 10.1055/s-2000-8487
   GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397
   Goris AHC, 2001, AM J CLIN NUTR, V73, P549
   Herman CP, 1980, OBESITY, V0, P208
   Hongu N, 2000, J NUTR, V130, P152, DOI 10.1093/jn/130.2.152
   HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968
   Hulshof KFAM, 2003, EUR J CLIN NUTR, V57, P128, DOI 10.1038/sj.ejcn.1601503
   Kao YH, 2000, ENDOCRINOLOGY, V141, P980, DOI 10.1210/en.141.3.980
   Kolaczynski JW, 1996, DIABETES, V45, P1511, DOI 10.2337/diabetes.45.11.1511
   Kovacs EMR, 2004, BRIT J NUTR, V91, P431, DOI 10.1079/BJN20041061
   KRAMER FM, 1989, INT J OBESITY, V13, P123
   KROMHOUT D, 1983, AM J CLIN NUTR, V38, P591, DOI 10.1093/ajcn/38.4.591
   LICHTENBELT WDV, 1994, BRIT J NUTR, V72, P491, DOI 10.1079/BJN19940053
   NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947
   Pasman WJ, 1997, INT J OBESITY, V21, P1143, DOI 10.1038/sj.ijo.0800528
   Pasman WJ, 1997, INT J OBESITY, V21, P548, DOI 10.1038/sj.ijo.0800439
   Pasman WJ, 1999, METABOLISM, V48, P15, DOI 10.1016/S0026-0495(99)90004-5
   Rumpler W, 2001, J NUTR, V131, P2848, DOI 10.1093/jn/131.11.2848
   Schoffelen PFM, 1997, J APPL PHYSIOL, V83, P2064, DOI 10.1152/jappl.1997.83.6.2064
   SEIDELL JC, 1995, OBES RES, V3, PS89, DOI 10.1002/j.1550-8528.1995.tb00451.x
   STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8
   TOUBRO S, 1993, INT J OBESITY, V17, P0
   Trayhurn P, 1999, INTERNATIONAL JOURNAL OF OBESITY, V23, P0
   VanGaal LF, 1997, INT J OBESITY, V21, P0
   WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925
   WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363
   Westerterp-Plantenga MS, 2004, INT J OBESITY, V28, P57, DOI 10.1038/sj.ijo.0802461
   Westerterp-Plantenga MS, 1998, INT J OBESITY, V22, P1, DOI 10.1038/sj.ijo.0800536
   Westerterp-Plantenga MS, 2001, AM J CLIN NUTR, V74, P426
   Westerterp-Plantenga MS, 1999, EUR J CLIN NUTR, V53, P495, DOI 10.1038/sj.ejcn.1600782
   WING RR, 1992, AM J CLIN NUTR, V55, P1086, DOI 10.1093/ajcn/55.6.1086
NR 39
TC 239
Z9 263
U1 2
U2 89
PU NORTH AMER ASSOC STUDY OBESITY
PI SILVER SPRING
PA 8630 FENTON ST, SUITE 918, SILVER SPRING, MD 20910 USA
SN 1071-7323
EI 
J9 OBES RES
JI Obes. Res.
PD JUL 15
PY 2005
VL 13
IS 7
BP 1195
EP 1204
DI 10.1038/oby.2005.142
PG 10
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 955GE
UT WOS:000231212800011
PM 16076989
DA 2025-04-28
ER

PT J
AU Greenberg, JA
   Axen, KV
   Schnoll, R
   Boozer, CN
AF Greenberg, JA
   Axen, KV
   Schnoll, R
   Boozer, CN
TI Coffee, tea and diabetes: the role of weight loss and caffeine
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
DE coffee; tea; beverages; caffeine; diabetes risk; weight loss
ID glucose-tolerance; consumption; risk; men; mellitus; obese
AB OBJECTIVE: To assess the effect of weight change on the relationship between coffee and tea consumption and diabetes risk. DESIGN: Prospective cohort study, using data from the First National Health and Nutrition Examination Survey Epidemiologic Follow Up Study. Survival analyses were conducted using 301 selfreported cases of diabetes and eight documented diabetes deaths during an 8.4-y follow-up. SUBJECTS: A total of 7006 subjects aged 32-88 y with no reported history of diabetes were included in the study. RESULTS: For all subjects combined, increases in consumption of ground-caffeinated coffee and caffeine at baseline were followed by decreases in diabetes risk during follow-up. There were significant statistical interactions between age and consumption of caffeine (P = 0.02) and ground-caffeinated coffee (P = 0.03). Age-stratified analysis showed that the decrease in diabetes risk only applied to <= 60-y-old subjects, for whom the decrease in diabetes risk also obtained for ground-decaffeinated coffee and regular tea. The multivariate hazard ratio (HR) and 95% confidence interval for a 2 cups/day increment in the intake of ground-caffeinated coffee, ground-decaffeinated coffee and regular tea was 0.86 (0.75-0.99), 0.58 (0.34-0.99) and 0.77 (0.59-1.00), respectively. The diabetes risk was negatively related to the consumption in a dose-response manner. There were strong statistical interactions between prior weight change and beverage consumption for <= 60-y-old subjects. Further analysis revealed that the decrease in diabetes risk only applied to those who had lost weight, and that there was a positive dose response relationship between diabetes risk and weight change. For example, the multivariate HR and 95% confidence interval for 40 vs 0 cups/day of ground-decaffeinated coffee was 0.17 (0.04-0.74), 0.52 (0.19-1.42), 0.77 (0.30-1.96) and 0.91 (0.39-2.14)for subgroups with weight change of <= 0, 0-10, 10-20 and > 20 lbs, respectively. There was no significant association between diabetes risk and consumption of instant-caffeinated coffee, instant-decaffeinated coffee or herbal tea. Caffeine intake appeared to explain some, but not all, of the diabetes-risk reduction and weight change. CONCLUSION: The negative relationship between diabetes risk and consumption of ground coffee and regular tea, observed for all NHEFS subjects, actually only applied to nonelderly adults who had previously lost weight.
C1 CUNY Brooklyn Coll, Dept Hlth & Nutr Sci, Brooklyn, NY 11210 USA.
   St Lukes Roosevelt Hosp, New York Obes Res Ctr, Energy Metab Core Lab, Bronx, NY USA.
   Columbia Univ, Ctr Med, Inst Human Nutr, Dept Med, New York, NY USA.
C3 City University of New York (CUNY) System; Brooklyn College (CUNY); Mount Sinai West; Mount Sinai St. Luke's; Columbia University
RP CUNY Brooklyn Coll, Dept Hlth & Nutr Sci, 2900 Bedford Ave, Brooklyn, NY 11210 USA.
EM jamesg@brooklyn.cuny.edu
CR Agardh EE, 2004, J INTERN MED, V255, P645, DOI 10.1111/j.1365-2796.2004.01331.x
   Arciero PJ, 2000, METABOLISM, V49, P101, DOI 10.1016/S0026-0495(00)90888-6
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   ASTRUP A, 1993, INT J OBESITY, V17, P0
   BRACCO D, 1995, AM J PHYSIOL-ENDOC M, V269, PE671, DOI 10.1152/ajpendo.1995.269.4.E671
   *BUNK MCW, 1979, 8 USDA, V0, P0
   COX DR, 1972, J R STAT SOC B, V34, P187
   Dulloo AG, 1999, AM J CLIN NUTR, V70, P1040
   Greenberg JA, 2001, INT J OBESITY, V25, P1071, DOI 10.1038/sj.ijo.0801648
   HARRIS MI, 1998, DIABETES CARE, V21, P475
   HILLAR P, 1973, VITAL HLTH STAT SER, V1, P0
   Isogawa A, 2003, LANCET, V361, P703, DOI 10.1016/S0140-6736(03)12586-X
   Johnston KL, 2003, AM J CLIN NUTR, V78, P728, DOI 10.1093/ajcn/78.4.728
   KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915
   *NAT COFF ASS, 2000, COFF DRINK TRENDS SU, V0, P0
   *NAT CTR HLTH STAT, 1987, VITAL HLTH STAT SER, V1, P0
   Reunanen A, 2003, LANCET, V361, P702, DOI 10.1016/S0140-6736(03)12583-4
   Rosengren A, 2004, J INTERN MED, V255, P89, DOI 10.1046/j.1365-2796.2003.01260.x
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   Saremi A, 2003, DIABETES CARE, V26, P2211, DOI 10.2337/diacare.26.7.2211
   *SPSS INC, 1997, ADV STAT 7 5, V0, P285
   Tabachnick BG, 1996, USING MUTIVARIATE STATISTICS, V0, P0
   *TEA ASS US INC, 2004, TEA FACT SHEET, V0, P0
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   *USDA, 1967, AGR HDB REV COMP FOO, V0, P0
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   van Dam RM, 2002, ANN INTERN MED, V136, P201, DOI 10.7326/0003-4819-136-3-200202050-00008
NR 27
TC 132
Z9 145
U1 1
U2 60
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD SEP 15
PY 2005
VL 29
IS 9
BP 1121
EP 1129
DI 10.1038/sj.ijo.0802999
PG 9
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 954CC
UT WOS:000231130700014
PM 15925959
DA 2025-04-28
ER

PT J
AU Ruzzin, J
   Lai, YC
   Jensen, J
AF Ruzzin, J
   Lai, YC
   Jensen, J
TI Consumption of carbohydrate solutions enhances energy intake without increased body weight and impaired insulin action in rat skeletal muscles
SO DIABETES & METABOLISM
LA English
DT Article
DE diet; soft drinks; beverages; obesity; catecholamines; fructose; sucrose
ID sympathetic-nervous-system; protein-kinase b; glycogen-synthesis; adipose-tissue; fructose; sucrose; resistance; glucose; diet; caffeine
AB Objectives: In the present study, we investigated whether replacement of tap water by fructose or sucrose solutions affect rat body weight and insulin action in skeletal muscles. Methods: Rats were fed standard rodent chow ad libitum with water, or water containing fructose (10.5% or 35%) or sucrose (10,5% or 35%) for 11 weeks. Body weight and energy intake from chow and drinking solutions were measured. Urinary catecholamines secretion was determined after 50-60 days. At the end of the feeding period, soleus and epitrochlearis were removed for in vitro measurements of glucose uptake (with tracer amount of 2- [H-3]-deoxy-D-glucose) and PKB Ser(473) phosphorylation (assessed by Western Blot) with or without insulin. Results: Fructose and sucrose solutions enhanced daily energy intake by about 15% without increasing rat body weight. Secretion of urinary noradrenaline was higher in rats drinking a 35% sucrose solution than in rats drinking water. In the other groups, urinary noradrenaline secretion was similar to rats consuming water. Urinary adrenaline secretion was similar in all groups. Insulin-stimulated glucose uptake and insulin-stimulated PKB phosphorylation were not reduced by intake of fructose or sucrose solution. Conclusions: Fructose and sucrose solutions enhanced energy intake but did not increase body weight. Although noradrenaline may regulate body weight in rats drinking 35% sucrose solution, body weight seems to be regulated by other mechanisms. Intake of fructose or sucrose solution did not impair insulin-stimulated glucose uptake or signaling in skeletal muscles.
C1 Natl Inst Occupat Hlth, Dept Physiol, N-0033 Oslo, Norway.
RP Natl Inst Occupat Hlth, Dept Physiol, POB 8149 Dep, N-0033 Oslo, Norway.
EM jorgen.jensen@stami.no
CR ACHESON KJ, 1980, AM J CLIN NUTR, V33, P989, DOI 10.1093/ajcn/33.5.989
   APUVIAN CM, 2004, JAMA-J AM MED ASSOC, V292, P978
   Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001
   Aslesen R, 1998, AM J PHYSIOL-ENDOC M, V275, PE448, DOI 10.1152/ajpendo.1998.275.3.E448
   Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160
   BECKNIELSEN H, 1980, AM J CLIN NUTR, V33, P273, DOI 10.1093/ajcn/33.2.273
   BELLET S, 1969, METABOLIS, V18, P288, DOI 10.1016/0026-0495(69)90049-3
   Bezerra RMN, 2000, J NUTR, V130, P1531, DOI 10.1093/jn/130.6.1531
   Block G, 2004, J FOOD COMPOS ANAL, V17, P439, DOI 10.1016/j.jfca.2004.02.007
   Bray GA, 2004, AM J CLIN NUTR, V79, P537
   BUKOWIECKI LJ, 1983, AM J PHYSIOL, V244, PR500, DOI 10.1152/ajpregu.1983.244.4.R500
   Choi SB, 2002, J NUTR BIOCHEM, V13, P727, DOI 10.1016/S0955-2863(02)00216-4
   CHOU T, 1992, WESTERN J MED, V157, P544
   Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082
   COTTETEMARD JM, 1980, J NEURAL TRANSM, V48, P189, DOI 10.1007/BF01243503
   DAI S, 1995, J PHARMACOL TOX MET, V33, P101, DOI 10.1016/1056-8719(94)00063-A
   Dulloo AG, 2002, SCIENCE, V297, P780, DOI 10.1126/science.1074923
   EIFFERT KC, 1993, J GERONTOL, V48, PB206, DOI 10.1093/geronj/48.6.B206
   El Yacoubi M, 2000, BRIT J PHARMACOL, V129, P1465, DOI 10.1038/sj.bjp.0703170
   French SA, 2001, ANNU REV PUBL HEALTH, V22, P309, DOI 10.1146/annurev.publhealth.22.1.309
   Gross LS, 2004, AM J CLIN NUTR, V79, P774
   Hay M, 2000, J ANIM SCI, V78, P420
   HILL R, 1954, J BIOL CHEM, V209, P705
   HOLMES C, 1994, J CHROMATOGR B, V653, P131, DOI 10.1016/0378-4347(93)E0430-X
   HOWRD BV, 2002, AM J MED S9B, V113, P0
   Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547
   Jensen J, 2002, PFLUG ARCH EUR J PHY, V444, P213, DOI 10.1007/s00424-002-0793-1
   Jiang ZY, 2003, P NATL ACAD SCI USA, V100, P7569, DOI 10.1073/pnas.1332633100
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LANDSBERG L, 1978, NEW ENGL J MED, V298, P1295, DOI 10.1056/NEJM197806082982306
   LANDSBERG L, 1983, AM J CLIN NUTR, V38, P1018, DOI 10.1093/ajcn/38.6.1018
   Lentner C, 1981, GEIGY SCI TABLES, V8th, P0
   Levi B, 1998, J NUTR, V128, P1442, DOI 10.1093/jn/128.9.1442
   LEVI L, 1967, ACTA MED SCAND, V181, P431
   Levine James A, 1999, SCIENCE (WASHINGTON D C), V283, P212, DOI 10.1126/science.283.5399.212
   Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527
   Lowry OH, 1972, FLEXIBLE SYSTEM ENZY, V0, P1
   Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1
   MAEGAWA H, 1986, AM J PHYSIOL, V251, PE616, DOI 10.1152/ajpendo.1986.251.5.E616
   Newby PK, 2004, J AM DIET ASSOC, V104, P1086, DOI 10.1016/j.jada.2004.04.020
   Pagliassotti MJ, 1996, AM J PHYSIOL-REG I, V271, PR1319, DOI 10.1152/ajpregu.1996.271.5.R1319
   Pagliassotti MJ, 2002, AM J PHYSIOL-ENDOC M, V282, PE170, DOI 10.1152/ajpendo.2002.282.1.E170
   PAGLIASSOTTI MJ, 1994, AM J PHYSIOL, V266, PR1637, DOI 10.1152/ajpregu.1994.266.5.R1637
   PAGLIASSOTTI MJ, 1995, AM J PHYSIOL-REG I, V269, PR641, DOI 10.1152/ajpregu.1995.269.3.R641
   Qin B, 2004, HORM METAB RES, V36, P119, DOI 10.1055/s-2004-814223
   Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927
   Seals DR, 2004, DIABETES, V53, P276, DOI 10.2337/diabetes.53.2.276
   Stark AH, 2000, EUR J NUTR, V39, P229, DOI 10.1007/s003940070016
   Strack AM, 1997, AM J PHYSIOL-REG I, V272, PR840, DOI 10.1152/ajpregu.1997.272.3.R840
   THORBURN AW, 1989, AM J CLIN NUTR, V49, P1155, DOI 10.1093/ajcn/49.6.1155
   Thresher JS, 2000, AM J PHYSIOL-REG I, V279, PR1334, DOI 10.1152/ajpregu.2000.279.4.R1334
   TOPPING DL, 1971, NUTR METAB, V13, P331
   Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315
   VRANA A, 1978, METABOLISM, V27, P885, DOI 10.1016/0026-0495(78)90131-2
   VRANA A, 1978, NUTR METAB, V22, P313
   WALGREN MC, 1987, METABOLISM, V36, P585, DOI 10.1016/0026-0495(87)90172-7
   Wang QH, 1999, MOL CELL BIOL, V19, P4008
   Webber J, 2003, P NUTR SOC, V62, P539, DOI 10.1079/PNS2003256
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wood IS, 2003, BRIT J NUTR, V89, P3, DOI 10.1079/BJN2002763
   YOUNG JB, 1977, NATURE, V269, P615, DOI 10.1038/269615a0
   YOUNG JB, 1977, CLIN RES, V25, P0
   YOUNG JB, 1981, AM J PHYSIOL, V240, PE314, DOI 10.1152/ajpendo.1981.240.3.E314
NR 63
TC 7
Z9 8
U1 0
U2 5
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 1262-3636
EI 1878-1780
J9 DIABETES METAB
JI Diabetes Metab.
PD APR 15
PY 2005
VL 31
IS 2
BP 178
EP 188
DI 10.1016/S1262-3636(07)70184-2
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 921FG
UT WOS:000228749000011
PM 15959424
DA 2025-04-28
ER

PT J
AU Wu, TY
   Hankinson, SE
   Willett, WC
   Giovannucci, E
AF Wu, TY
   Hankinson, SE
   Willett, WC
   Giovannucci, E
TI Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in US women
SO DIABETES CARE
LA English
DT Article
ID glucose disposal; consumption; risk; reproducibility; resistance; ingestion; validity; blood; model; acid
AB OBJECTIVE - Coffee consumption is associated with reduced risk of type 2 diabetes, but the mechanism is not clearly understood. Elevated C-peptide, as a marker of insulin secretion, has been linked to insulin-resistant type 2 diabetes. In this study, we examined consumption of caffeinated and decaffeinated coffee and total caffeine in relation to concentrations of plasma C-peptide. RESEARCH DESIGN AND METHODS - Plasma C-peptide concentrations were measured in a cross-sectional setting among 2,112 healthy women from the Nurses' Health Study I who provided blood samples in 1989-1990. Consumption of caffeinated and decaffeinated coffee and total caffeine was assessed using a semiquantitative food-frequency questionnaire in 1990. RESULTS - intakes of caffeinated and decaffeinated coffee and caffeine in 1990 were each inversely associated with C-peptide concentration in age-adjusted, BMI-adjusted, and multivariable-adjusted analyses. In multivariable analysis, concentrations of C-peptide were 16% less in women who drank > 4 cups/day of caffeinated or decaffeinated coffee compared with nondrinkers (P < 0.005 for each). Women in the highest quintile compared with the lowest quintile of caffeine intake had 10% lower C-pepticle levels (P = 0.02). We did not find any association between tea and C-peptide. The inverse association between caffeinated coffee and C-peptide was considerably stronger in obese (27% reduction) and overweight women (20% reduction) than in normal weight women (11% reduction) (P = 0.005). CONCLUSIONS - Our findings suggest a potential reduction of insulin secretion by coffee in women. This reduction may be related to other components in coffee rather than caffeine.
C1 Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
   Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA USA.
   Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard University Medical Affiliates; Brigham & Women's Hospital
RP Harvard Univ, Sch Publ Hlth, Dept Nutr, 655 Huntington Ave, Boston, MA 02115 USA.
EM tianying@hsph.harvard.edu
FU NCI NIH HHS [5P01 CA 87969, CA 49449] Funding Source: Medline; NIDDK NIH HHS [5R01 DK 58845] Funding Source: Medline
CR Arion WJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P315, DOI 10.1006/abbi.1996.9874
   Ärnlöv J, 2004, JAMA-J AM MED ASSOC, V291, P1199, DOI 10.1001/jama.291.10.1199-b
   ASTRUP A, 1990, AM J CLIN NUTR, V51, P759, DOI 10.1093/ajcn/51.5.759
   Boozer CN, 2002, INT J OBESITY, V26, P593, DOI 10.1038/sj.ijo.0802023
   BROWN CR, 1989, PHARMACOL BIOCHEM BE, V34, P565, DOI 10.1016/0091-3057(89)90559-5
   Bruce CR, 2003, DIABETES, V52, P2338, DOI 10.2337/diabetes.52.9.2338
   Chen CH, 1999, INT J CARDIOL, V68, P179, DOI 10.1016/S0167-5273(98)00366-0
   CHERASKIN E, 1968, LANCET, V2, P689
   Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49
   Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349
   Haban Peter, 2002, MED SCI MONIT, V8, P0
   Haffner SM, 1996, DIABETES CARE, V19, P1138, DOI 10.2337/diacare.19.10.1138
   HANKINSON SE, 1989, CLIN CHEM, V35, P2313
   JACOB S, 1995, ARZNEIMITTEL-FORSCH, V45-2, P872
   JENKINS DJA, 1988, AM J CLIN NUTR, V48, P248, DOI 10.1093/ajcn/48.2.248
   Kaaks R, 2000, JNCI-J NATL CANCER I, V92, P1592, DOI 10.1093/jnci/92.19.1592
   Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Meyer KA, 2003, J AM COLL NUTR, V22, P185, DOI 10.1080/07315724.2003.10719292
   Rimm E B, 1990, EPIDEMIOLOGY, V1, P466, DOI 10.1097/00001648-199011000-00009
   ROBERTSON D, 1981, J CLIN INVEST, V67, P1111, DOI 10.1172/JCI110124
   Salazar-Martinez E, 2004, ANN INTERN MED, V140, P1, DOI 10.7326/0003-4819-140-1-200401060-00005
   SPRIET LL, 1992, AM J PHYSIOL, V262, PE891, DOI 10.1152/ajpendo.1992.262.6.E891
   Svilaas A, 2004, J NUTR, V134, P562, DOI 10.1093/jn/134.3.562
   Thirunavukkarasu V, 2004, DIABETES OBES METAB, V6, P200, DOI 10.1111/j.1462-8902.2004.00332.x
   Tuomilehto J, 2004, JAMA-J AM MED ASSOC, V291, P1213, DOI 10.1001/jama.291.10.1213
   van Dam RM, 2002, LANCET, V360, P1477, DOI 10.1016/S0140-6736(02)11436-X
   Wahren J, 2000, AM J PHYSIOL-ENDOC M, V278, PE759, DOI 10.1152/ajpendo.2000.278.5.E759
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Willett WC, 1997, AM J CLIN NUTR, V65, P1220, DOI 10.1093/ajcn/65.4.1220S
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Willett WC, 1998, NUTR EPIDEMIOLOGY, V0, P0
   WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991
   Wu TY, 2004, AM J CLIN NUTR, V80, P1043, DOI 10.1093/ajcn/80.4.1043
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 36
TC 120
Z9 128
U1 0
U2 5
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN 15
PY 2005
VL 28
IS 6
BP 1390
EP 1396
DI 10.2337/diacare.28.6.1390
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 931QM
UT WOS:000229500000019
PM 15920057
DA 2025-04-28
ER

PT J
AU Haller, CA
   Jacob, P
   Benowitz, NL
AF Haller, CA
   Jacob, P
   Benowitz, NL
TI Short-term metabolic and hemodynamic effects of ephedra and guarana combinations
SO CLINICAL PHARMACOLOGY & THERAPEUTICS
LA English
DT Article
ID dietary-supplement; ma-huang; healthy-volunteers; caffeine; pharmacokinetics; multicomponent; pharmacology; alkaloids; sinica
AB Objective: Serious adverse health events have been reported with the use of dietary supplements containing ephedra and guarana. We sought to determine whether repeated dosing and multi-ingredient formulations contribute to the adverse effects of these supplements. Methods. In this study, 16 healthy adults (8 women) took 2 doses each of ephedra-guarana alone, Xenadrine RFA, a multicomponent dietary supplement containing 25 mg ephedra alkaloids and 200 mg caffeine, or placebo 5 hours apart in a randomized, double-blind, 3-arm crossover study. Results. Peak plasma ephedrine levels averaged 130 to 140 ng/mL. Compared with placebo, Xenadrine and ephedra-guarana significantly increased heart rate (maximum increase, 9.4 +/- 8.6 beats/min; P = .002), blood pressure (maximum increase in systolic and diastolic pressure, 11.5 +/- 10.7 min Hg and 7.3 +/- 7.4 min Hg, respectively; P = .015), postprandial glucose concentration (maximum change, 41.0 +/- 18.8 mg/dL; P < .0001), and insulin concentration (maximum change, 41.2 +/- 47.8 mu IU/mL; P = .005). Serum potassium concentrations were significantly decreased by both treatments. Hemodynamic and metabolic changes were observed after both the first and second doses. However, plasma free fatty acid concentrations increased after the first dose only. Xenadrine RFA produced higher increases in glucose concentration than ephedra-guarana, but no other pharmacodynamic differences between the treatments were found. Conclusions: Consumption of 2 doses of ephedra and guarana supplements, per supplement label recommendations, results in persistent increases in heart rate and blood pressure and unfavorable actions on glucose and potassium homeostasis. Such effects could be detrimental in persons with hypertension, atherosclerosis, or glucose intolerance, conditions that are strongly associated with obesity.
C1 Univ Calif San Francisco, Dept Med, Div Clin Pharmacol, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco
RP Haller, CA (corresponding author), Univ Calif San Francisco, Dept Med, Div Clin Pharmacol, Box 1220, San Francisco, CA 94143 USA.
EM dchaller@worldnet.att.net
FU NCCIH NIH HHS [K23AT00069-04] Funding Source: Medline; NCRR NIH HHS [M01RR00083-41] Funding Source: Medline; NIDA NIH HHS [DA12393] Funding Source: Medline; National Institute on Drug Abuse [P30DA012393] Funding Source: NIH RePORTER
CR ASTRUP A, 1991, METABOLISM, V40, P323, DOI 10.1016/0026-0495(91)90117-F
   ASTRUP A, 1986, ACTA ENDOCRINOLOGICA SUPPLEMENTUM, V112, P1
   BYE C, 1975, EUR J CLIN PHARMACOL, V8, P47, DOI 10.1007/BF00616414
   COSTELLO JF, 1975, BRIT J CLIN PHARMACO, V2, P0
   DICKERSON J, 1978, EUR J CLIN PHARMACOL, V14, P253, DOI 10.1007/BF00560458
   DULLOO AG, 1986, INT J OBESITY, V10, P467
   Gardner SF, 2003, AM J CARDIOL, V91, P1510, DOI 10.1016/S0002-9149(03)00413-2
   Gurley BJ, 1998, THER DRUG MONIT, V20, P439, DOI 10.1097/00007691-199808000-00015
   Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502
   Haller CA, 2004, CLIN PHARMACOL THER, V75, P259, DOI 10.1016/j.clpt.2003.11.375
   Haller CA, 2002, CLIN PHARMACOL THER, V71, P421, DOI 10.1067/mcp.2002.124523
   Horton TJ, 1996, INT J OBESITY, V20, P91
   Jacob P, 2004, J ANAL TOXICOL, V28, P152, DOI 10.1093/jat/28.3.152
   Kockler DR, 2001, PHARMACOTHERAPY, V21, P647, DOI 10.1592/phco.21.6.647.34542
   LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442
   Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201
   McBride BF, 2004, JAMA-J AM MED ASSOC, V291, P216, DOI 10.1001/jama.291.2.216
   PATIL PN, 1965, J PHARMACOL EXP THER, V148, P158
   PENTEL P, 1984, JAMA-J AM MED ASSOC, V252, P1898, DOI 10.1001/jama.252.14.1898
   SACCA L, 1983, AM J PHYSIOL, V245, PE294, DOI 10.1152/ajpendo.1983.245.3.E294
   Samenuk D, 2002, MAYO CLIN PROC, V77, P12, DOI 10.4065/77.1.12
   SAWYNOK J, 1993, PHARMACOL REV, V45, P43
   Schier JG, 2003, J TOXICOL-CLIN TOXIC, V41, P849, DOI 10.1081/CLT-120025350
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   Vahedi K, 2000, J NEUROL NEUROSUR PS, V68, P112, DOI 10.1136/jnnp.68.1.112
   White LM, 1997, J CLIN PHARMACOL, V37, P116, DOI 10.1002/j.1552-4604.1997.tb04769.x
NR 28
TC 43
Z9 49
U1 0
U2 11
PU MOSBY, INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA
SN 0009-9236
EI 
J9 CLIN PHARMACOL THER
JI Clin. Pharmacol. Ther.
PD JUN 15
PY 2005
VL 77
IS 6
BP 560
EP 571
DI 10.1016/j.clpt.2005.01.023
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 935EU
UT WOS:000229763200012
PM 15961987
DA 2025-04-28
ER

PT J
AU Wilsgaard, T
   Jacobsen, BK
   Arnesen, E
AF Wilsgaard, T
   Jacobsen, BK
   Arnesen, E
TI Determining lifestyle correlates of body mass index using multilevel analyses: The Tromso study, 1979-2001
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE body mass index; longitudinal studies; obesity; population; sex
ID cardiovascular risk-factors; middle-aged men; nutrition examination survey; 3rd national-health; international perspective; socioeconomic differences; educational-level; physical-activity; monica project; blood-pressure
AB Increases in overweight and obesity have been observed globally in both developed and developing countries. The authors assessed the relation between lifestyle factors and body mass index (BMI) (weight (kg)/height (m)(2)) in a population-based longitudinal study, using BMI and its subsequent change as responses in a multilevel model. The authors included 11,115 men and women aged 20-61 years at baseline who were living in the municipality of Tromso, Norway, and who participated in three or four consecutive health surveys between 1979-1980 and 2001. Baseline age, physical activity at work, coffee consumption, and desired BMI (i.e., the BMI that the subjects reported they would like to have) were positively associated with baseline BMI, whereas height, alcohol consumption, leisure-time physical activity, and level of education were inversely associated. Most relations were found to be stronger in women than in men. Clinically relevant effect sizes were observed for most of the significant associations, especially in women. For instance, on an ordinal scale, a one-category increase in educational level would decrease the mean baseline BMI among women by 0.30 kg/m(2). Significant associations between several lifestyle factors and subsequent BMI change revealed that observed baseline associations were strengthened over time, especially in women.
C1 Univ Tromso, Fac Med, Inst Community Med, N-9037 Tromso, Norway.
C3 UiT The Arctic University of Tromso
RP Wilsgaard, T (corresponding author), Univ Tromso, Fac Med, Inst Community Med, N-9037 Tromso, Norway.
EM tom.wilsgaard@ism.uit.no
CR Unknown -, 2003, WHO TECH REP SER, V916, P1
   Unknown -, 2017, ANNEX 3-03, V0, P4
   BONAA KH, 1991, CIRCULATION, V83, P1305, DOI 10.1161/01.CIR.83.4.1305
   BONAA KH, 1992, CIRCULATION, V86, P394
   Cameron AJ, 2003, MED J AUSTRALIA, V178, P427, DOI 10.5694/j.1326-5377.2003.tb05283.x
   Cho S, 2003, J AM COLL NUTR, V22, P296, DOI 10.1080/07315724.2003.10719307
   Droyvold WB, 2004, INT J OBESITY, V28, P410, DOI 10.1038/sj.ijo.0802569
   FOSS OP, 1986, SCAND J CLIN LAB INV, V46, P245, DOI 10.3109/00365518609083666
   HUBERT HB, 1987, AM J EPIDEMIOL, V125, P812, DOI 10.1093/oxfordjournals.aje.a114598
   JACOBSEN BK, 1987, SCAND J SOC MED, V15, P41, DOI 10.1177/140349488701500107
   JACOBSEN BK, 1987, J CHRON DIS, V40, P795, DOI 10.1016/0021-9681(87)90131-7
   JEFFERY RW, 1989, INT J OBESITY, V13, P59
   Jousilahti P, 1996, CIRCULATION, V93, P1372, DOI 10.1161/01.CIR.93.7.1372
   Kawada T, 2004, ARCH MED RES, V35, P181, DOI 10.1016/j.arcmed.2003.09.012
   Laaksonen M, 1998, PREV MED, V27, P431, DOI 10.1006/pmed.1998.0288
   Lahti-Koski M, 2000, AM J CLIN NUTR, V72, P1436
   LamonFava S, 1996, ARTERIOSCL THROM VAS, V16, P1509, DOI 10.1161/01.ATV.16.12.1509
   Lin YC, 2003, PREV MED, V37, P233, DOI 10.1016/S0091-7435(03)00119-1
   LOCHEN ML, 1992, J EPIDEMIOL COMMUNIT, V43, P103
   MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57
   Marques-Vidal P, 2001, ATHEROSCLEROSIS, V157, P431, DOI 10.1016/S0021-9150(00)00734-6
   Martikainen PT, 1999, AM J CLIN NUTR, V69, P719
   Molarius A, 1997, J EPIDEMIOL COMMUN H, V51, P252, DOI 10.1136/jech.51.3.252
   Molarius A, 2000, AM J PUBLIC HEALTH, V90, P1260, DOI 10.2105/AJPH.90.8.1260
   Myllykangas M, 1995, INT J EPIDEMIOL, V24, P1110, DOI 10.1093/ije/24.6.1110
   Petersen L, 2004, INT J OBESITY, V28, P105, DOI 10.1038/sj.ijo.0802548
   Rasky E, 1996, INT J EPIDEMIOL, V25, P1208, DOI 10.1093/ije/25.6.1208
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, V2, P0
   Seidell JC, 2000, BRIT J NUTR, V83, PS5, DOI 10.1017/S000711450000088X
   Singer D, 2003, APPL LONGITUDINAL DA, V0, P0, DOI DOI 10.1093/ACPROF:OSO/9780195152968.003.0015
   Stamler J, 1991, ANN EPIDEMIOL, V1, P347, DOI 10.1016/1047-2797(91)90045-E
   Sundquist J, 1998, INT J EPIDEMIOL, V27, P57, DOI 10.1093/ije/27.1.57
   THELLE DS, 1976, ACTA MED SCAND, V200, P107
   Wannamethee SG, 2003, AM J CLIN NUTR, V77, P1312, DOI 10.1093/ajcn/77.5.1312
   Wilhelmsen L, 1976, ADV CARDIOL, V18, P217
   Wilsgaard T, 2000, ARCH INTERN MED, V160, P2847, DOI 10.1001/archinte.160.18.2847
   Wilsgaard T, 2004, ANN EPIDEMIOL, V14, P265, DOI 10.1016/j.annepidem.2003.08.004
   Wilsgaard T, 2001, AM J EPIDEMIOL, V154, P418, DOI 10.1093/aje/154.5.418
   Winkleby MA, 1998, JAMA-J AM MED ASSOC, V280, P356, DOI 10.1001/jama.280.4.356
NR 40
TC 40
Z9 45
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD DEC 15
PY 2005
VL 162
IS 12
BP 1179
EP 1188
DI 10.1093/aje/kwi328
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 991YI
UT WOS:000233850400006
PM 16269586
DA 2025-04-28
ER

PT J
AU Dwyer, JT
   Allison, DB
   Coates, PM
AF Dwyer, JT
   Allison, DB
   Coates, PM
TI Dietary supplements in weight reduction
SO JOURNAL OF THE AMERICAN DIETETIC ASSOCIATION
LA English
DT Article
ID body-weight; calcium intake; bone turnover; fat loss; overweight; efficacy; safety; restriction; obesity; adults
AB We summarize evidence on the role of dietary supplements in weight reduction, with particular attention to their safety and benefits. Dietary supplements are used for two purposes in weight reduction: (a) providing nutrients that may be inadequate in calorie-restricted diets and (b) for their potential benefits in stimulating weight loss. The goal in planning weight-reduction diets is that total intake from food and supplements should meet recommended dietary allowance/adequate intake levels without greatly exceeding them for all nutrients, except energy. If nutrient amounts from food sources in the reducing diet fall short, dietary supplements containing a single nutrient/element or a multivitamin-mineral combination may be helpful. On hypocaloric diets, the addition of dietary supplements providing nutrients at a level equal to or below recommended dietary allowance/adequate intake levels or 100% daily value, as stated in a supplement's facts box on the label, may help dieters to achieve nutrient adequacy and maintain electrolyte balance while avoiding the risk of excessive nutrient intakes. Many botanical and other types of dietary supplements are purported to be useful for stimulating or enhancing weight loss. Evidence of their efficacy in stimulating weight loss is inconclusive at present. Although there are few examples of safety concerns related to products that are legal and on the market for this purpose, there is also a paucity of evidence on safety for this intended use. Ephedra and ephedrine-containing supplements, with or without caffeine, have been singled out in recent alerts from the Food and Drug Administration because of safety concerns, and use of products containing these substances cannot be recommended. Dietitians should periodically check the Food and Drug Administration Web site (http://www.cfsan.fda.gov) for updates and warnings and alert patients/clients to safety concerns. Dietetics professionals should also consult authoritative sources for new data on efficacy as it becomes available (ods.od.nih.gov).
C1 NIH, Off Dietary Supplements, Bethesda, MD 20892 USA.
   Univ Alabama Birmingham, Sect Stat Genet, Dept Biostat, Birmingham, AL USA.
   Univ Alabama Birmingham, Clin Nutr Res Ctr, Dept Nutr Sci, Birmingham, AL USA.
C3 National Institutes of Health (NIH) - USA; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham
RP NIH, Off Dietary Supplements, 6100 Execut Blvd,Room 3B01 MSC 7517, Bethesda, MD 20892 USA.
EM DwyerJ1@od.nih.gov
CR Allison DB, 2001, CRIT REV FOOD SCI, V41, P1, DOI 10.1080/20014091091661
   Barr SI, 2003, J NUTR, V133, P0
   Bent S, 2004, AM J CARDIOL, V94, P1359, DOI 10.1016/j.amjcard.2004.07.137
   Black A, 2001, J GERONTOL A-BIOL, V56, PB98, DOI 10.1093/gerona/56.3.B98
   Bowen J, 2004, J NUTR, V134, P568, DOI 10.1093/jn/134.3.568
   BREUM L, 1994, INT J OBESITY, V2, P99
   Chamberlain A, 2004, NUTR CLIN CARE, V7, P19
   Cifuentes MC, 2004, AM J CLIN NUTR, V80, P123
   COLKER CM, 2004, J STRENGTH COND RES, V16, P1
   *COMM FRAM EV SAF, 2004, FOOD NUTR BOARD BOAR, V0, P0
   *CORP, 1993, JAMA-J AM MED ASSOC, V270, P967
   Crawford V, 1999, DIABETES OBES METAB, V1, P331, DOI 10.1046/j.1463-1326.1999.00055.x
   Egger G, 1999, MED J AUSTRALIA, V171, P604, DOI 10.5694/j.1326-5377.1999.tb123817.x
   FLIER J, 2004, HARRISONS PRINCIPLES, V0, P422
   Food and Drug Administration HHS, 2004, FED REGIST, V69, P6787
   [Food and Nutrition Board Institute of Medicine], 2004, DIET REF INT WAT POT, V0, P0
   Fugh-Berman A, 2004, EXP BIOL MED, V229, P698, DOI 10.1177/153537020422900802
   Goode LR, 2004, OBES RES, V12, P40, DOI 10.1038/oby.2004.7
   Gurley BJ, 2004, CLIN PHARMACOL THER, V75, PP35, DOI 10.1016/j.clpt.2003.11.134
   Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847
   Hunt J, 2001, J AM DIET ASSOC, V101, P115, DOI 10.1016/S0002-8223(01)00026-8
   Kroll DJ, 2004, AM J HEALTH-SYST PH, V61, P1707, DOI 10.1093/ajhp/61.16.1707
   Larsen TM, 2003, J LIPID RES, V44, P2234, DOI 10.1194/jlr.R300011-JLR200
   Lenz Thomas L, 2004, J AM PHARM ASSOC (2003), V44, P59, DOI 10.1331/154434504322713246
   Mhurchu CN, 2004, INT J OBESITY, V28, P1149, DOI 10.1038/sj.ijo.0802693
   *NAT I HLTH, 2004, NIH STRAT PLAN OB RE, V0, P0
   Pi-Sunyer FX, 1998, OBES RES, V6, P0
   Pittler MH, 2004, AM J CLIN NUTR, V79, P529
   Pittler MH, 2003, INT J OBESITY, V27, P522, DOI 10.1038/sj.ijo.0802262
   Risérus U, 2004, AM J CLIN NUTR, V79, P0
   Shapses SA, 2004, J CLIN ENDOCR METAB, V89, P632, DOI 10.1210/jc.2002-021136
   Shapses SA, 2001, J BONE MINER RES, V16, P1329, DOI 10.1359/jbmr.2001.16.7.1329
   Shekelle PG, 2003, JAMA-J AM MED ASSOC, V289, P1537, DOI 10.1001/jama.289.12.1537
   SQUIRES RD, 1959, J CLIN INVEST, V38, P1134, DOI 10.1172/JCI103890
   Thomson C, 2002, J AM DIET ASSOC, V102, P1158, DOI 10.1016/S0002-8223(02)90257-9
   Zemel MB, 2004, OBES RES, V12, P582, DOI 10.1038/oby.2004.67
   ZEMEL MB, 2004, IN PRESS OBES RES, V0, P0
NR 39
TC 66
Z9 79
U1 0
U2 23
PU AMER DIETETIC ASSOC
PI CHICAGO
PA 120 S RIVERSIDE PLZ, STE 2000, CHICAGO, IL 60606-6995 USA
SN 0002-8223
EI 
J9 J AM DIET ASSOC
JI J. Am. Diet. Assoc.
PD MAY 15
PY 2005
VL 105
IS 5
BP S80
EP S86
DI 10.1016/j.jada.2005.02.028
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 927VL
UT WOS:000229228500014
PM 15867902
DA 2025-04-28
ER

